Conditioned medium of olfactory ensheathing cells	1
Conditioned medium	1
olfactory ensheathing cells	23
the functional recovery and axonal regeneration	60
contusive spinal cord injury A B S T R A C T Objective	114
the effectiveness and the potential role of olfactory ensheathing cell conditioned medium -LRB- OEC-M -RRB-	186
the effectiveness	186
the potential role of olfactory ensheathing cell conditioned medium -LRB- OEC-M -RRB-	208
the potential role	208
olfactory ensheathing cell conditioned medium -LRB- OEC-M -RRB-	230
olfactory ensheathing cell conditioned medium	230
olfactory ensheathing cell	230
OEC-M	277
contusive spinal cord injury -LRB- SCI -RRB-	293
contusive spinal cord injury	293
SCI	323
Methods : The contusive SCI model was established by NYU weight-drop impactor at T10 segment .	329
Methods	329
The contusive SCI model	338
NYU weight-drop impactor	381
T10 segment	409
Male Sprague-Dawley rats	422
intraperitoneal injection of control medium -LRB- Con-M , n = 18 -RRB- , low dose OEC-M -LRB- n = 18 -RRB- and high dose OEC-M -LRB- n = 18 -RRB-	456
intraperitoneal injection	456
control medium -LRB- Con-M , n = 18 -RRB- , low dose OEC-M -LRB- n = 18 -RRB- and high dose OEC-M -LRB- n = 18 -RRB-	485
control medium -LRB- Con-M , n = 18 -RRB-	485
control medium	485
Con-M , n = 18	501
Con-M	501
n = 18	508
n	508
18	510
low dose OEC-M -LRB- n = 18 -RRB-	515
low dose OEC-M	515
n	531
18	533
high dose OEC-M -LRB- n = 18 -RRB-	541
high dose OEC-M	541
n	558
18	560
Immunofluorescence	565
the purity of cultured OECs	610
the purity	610
OECs	633
BBB score	639
the functional recovery	668
BDNF concentrations of OEC-M , Con-M and rats plasma samples	693
BDNF concentrations	693
OEC-M , Con-M and rats plasma samples	716
ELISA	772
Conventional MRI and diffusion tensor tractography -LRB- DTT -RRB-	779
Conventional MRI and diffusion tensor tractography	779
Conventional MRI	779
diffusion tensor tractography	800
DTT	831
the repair process of SCI	862
the repair process	862
SCI	884
Diffusion tensor imaging -LRB- DTI -RRB- and immunohistochemistry of NF200	889
Diffusion tensor imaging -LRB- DTI -RRB-	889
Diffusion tensor imaging	889
DTI	915
immunohistochemistry of NF200	924
immunohistochemistry	924
NF200	948
the axonal regeneration	983
Results	1008
the systemic delivery of treatment	1023
the systemic delivery	1023
treatment	1048
BBB scores and BDNF levels in peripheral blood	1059
BBB scores	1059
BDNF levels in peripheral blood	1074
BDNF levels	1074
peripheral blood	1089
OEC-M	1135
treated groups	1141
Con-M group	1164
MRI and DTT	1177
MRI	1177
DTT	1185
a better radiological recovery	1202
SCI	1239
OEC-M treated groups	1246
higher dose of OEC-M	1271
higher dose	1271
OEC-M	1286
better outcomes	1314
DTI and NF200 staining	1331
the OEC-M treatment	1363
axonal regeneration	1392
the injury epicenter	1419
no axonal regeneration	1444
the lesion site	1483
Conclusion	1500
The results	1512
the OEC-M treatment	1538
the functional recovery	1567
the axonal regeneration around the injury epicenter	1604
the axonal regeneration	1604
the injury epicenter	1635
contusive SCI	1662
This strategy	1677
a novel cell-free OEC based therapy to effectively treat SCI	1702
a novel cell-free OEC	1702
therapy	1730
SCI	1759
Introduction Spinal cord injury -LRB- SCI -RRB-	1768
Introduction Spinal cord injury	1768
Introduction	1768
Spinal cord injury	1781
SCI	1801
a devastating form of trauma resulting in the permanent loss of motor , sensory and autonomic function	1809
a devastating form	1809
trauma resulting in the permanent loss of motor , sensory and autonomic function	1831
trauma	1831
the permanent loss of motor , sensory and autonomic function	1851
the permanent loss	1851
motor , sensory and autonomic function	1873
motor	1873
sensory	1880
autonomic function	1892
the poor self-repair capability of central nerve system -LRB- CNS -RRB-	1919
the poor self-repair capability	1919
central nerve system -LRB- CNS -RRB-	1954
central nerve system	1954
CNS	1975
spinal cord injury	1981
a therapeutic challenge to date	2009
a therapeutic challenge	2009
date	2036
the last two decades	2047
a potential effective therapy for spinal cord injury	2072
a potential effective therapy	2072
spinal cord injury	2106
surgical transplantation of a series of cell types , including olfactory ensheathing cells -LRB- OECs -RRB- , Schwann cells , fate-restricted neural and glial precursors , undifferentiated neural stem cells , and bone marrow stromal cells	2126
surgical transplantation	2126
a series of cell types , including olfactory ensheathing cells -LRB- OECs -RRB- , Schwann cells , fate-restricted neural and glial precursors , undifferentiated neural stem cells , and bone marrow stromal cells	2154
a series	2154
cell types	2166
olfactory ensheathing cells -LRB- OECs -RRB- , Schwann cells , fate-restricted neural and glial precursors , undifferentiated neural stem cells , and bone marrow stromal cells	2188
olfactory ensheathing cells	2188
OECs	2217
Schwann cells	2224
fate-restricted neural and glial precursors	2239
undifferentiated neural stem cells	2284
bone marrow stromal cells	2324
Tetzlaff et al. , 2011	2390
Tetzlaff	2390
et al.	2399
2011	2407
OECs , derived from the nerve fiber layer of olfactory bulb and nasal mucosa ,	2414
OECs	2414
the nerve fiber layer of olfactory bulb and nasal mucosa	2433
the nerve fiber layer	2433
olfactory bulb and nasal mucosa	2458
olfactory bulb	2458
nasal mucosa	2477
the regeneration of primary olfactory system	2514
the regeneration	2514
primary olfactory system	2534
a lesion -LRB- Franssen et al. , 2007 -RRB-	2565
a lesion	2565
Franssen	2575
et al. , 2007	2584
et al.	2584
2007	2592
the new axons extending from olfactory epithelium to the olfactory bulb -LRB- Raisman , 1985 -RRB-	2624
the new axons	2624
olfactory epithelium	2653
the olfactory bulb -LRB- Raisman , 1985 -RRB-	2677
the olfactory bulb	2677
Raisman , 1985	2697
Raisman	2697
1985	2706
this axon growth promoting property	2724
this axon growth	2724
property	2751
OECs	2761
a promising candidate for the cell-based treatment of SCI	2799
a promising candidate	2799
the cell-based treatment of SCI	2825
the cell-based treatment	2825
SCI	2853
Earlier studies	2858
transplantation of OECs into spinal cord lesions	2897
transplantation	2897
OECs into spinal cord lesions	2916
OECs	2916
spinal cord lesions	2926
neural regeneration	2958
locomotor function	2987
progressive tissue loss	3015
axonal remyelination -LRB- Li et al. , 1998 ; Lopez-Vales et al. , 2006 ; Lu et al. , 2002 ; Pearse et al. , 2007 ; Plant et al. , 2003 ; Ramer et al. , 2004 ; Sasaki et al. , 2004 ; Ziegler et al. , 2011 -RRB-	3053
axonal remyelination	3053
Li et al. , 1998 ; Lopez-Vales et al. , 2006 ; Lu et al. , 2002 ; Pearse et al. , 2007 ; Plant et al. , 2003 ; Ramer et al. , 2004 ; Sasaki et al. , 2004 ; Ziegler et al. , 2011	3075
Li	3075
et al. , 1998 ; Lopez-Vales et al. , 2006 ; Lu et al. , 2002 ; Pearse et al. , 2007 ; Plant et al. , 2003 ; Ramer et al. , 2004 ; Sasaki et al. , 2004 ; Ziegler et al. , 2011	3078
et al. , 1998	3078
et al.	3078
1998	3086
Lopez-Vales et al. , 2006	3092
Lopez-Vales	3092
et al. , 2006	3104
et al.	3104
2006	3112
Lu et al. , 2002	3118
Lu	3118
et al. , 2002	3121
et al.	3121
2002	3129
Pearse et al. , 2007	3135
Pearse	3135
et al. , 2007	3142
et al.	3142
2007	3150
Plant et al. , 2003	3156
Plant	3156
et al. , 2003	3162
et al.	3162
2003	3170
Ramer et al. , 2004	3176
Ramer	3176
et al. , 2004	3182
et al.	3182
2004	3190
Sasaki et al. , 2004	3196
Sasaki	3196
et al. , 2004	3203
et al.	3203
2004	3211
Ziegler et al. , 2011	3217
Ziegler	3217
et al. , 2011	3225
et al.	3225
2011	3233
The mechanisms of the beneficial effects of OECs	3240
The mechanisms	3240
the beneficial effects of OECs	3258
the beneficial effects	3258
OECs	3284
their expression of various neurotrophic factors -LRB- Au et al. , 2007 ; Lipson et al. , 2003 ; Woodhall et al. , 2001 -RRB- and extracellular matrix components -LRB- Richter and Roskanis , 2008 -RRB- , interaction with reactive astrocytes -LRB- Chuah et al. , 2011 ; Franssen et al. , 2007 ; Richter and Roskanis , 2008 -RRB- , modulation of inflammatory response -LRB- Chuah et al. , 2011 ; Lopez-Vales et al. , 2004b ; Torres-Espin et al. , 2013 -RRB- , promotion of neoangiogenesis -LRB- Lopez-Vales et al. , 2004a -RRB-	3297
their expression of various neurotrophic factors -LRB- Au et al. , 2007 ; Lipson et al. , 2003 ; Woodhall et al. , 2001 -RRB- and extracellular matrix components -LRB- Richter and Roskanis , 2008 -RRB-	3297
their expression	3297
various neurotrophic factors -LRB- Au et al. , 2007 ; Lipson et al. , 2003 ; Woodhall et al. , 2001 -RRB- and extracellular matrix components -LRB- Richter and Roskanis , 2008 -RRB-	3317
various neurotrophic factors	3317
Au et al. , 2007 ; Lipson et al. , 2003 ; Woodhall et al. , 2001	3347
Au	3347
et al. , 2007 ; Lipson et al. , 2003 ; Woodhall et al. , 2001	3350
et al. , 2007	3350
et al.	3350
2007	3358
Lipson et al. , 2003	3364
Lipson	3364
et al. , 2003	3371
et al.	3371
2003	3379
Woodhall et al. , 2001	3385
Woodhall	3385
et al. , 2001	3394
et al.	3394
2001	3402
extracellular matrix components	3412
Richter and Roskanis	3445
2008	3467
interaction with reactive astrocytes -LRB- Chuah et al. , 2011 ; Franssen et al. , 2007 ; Richter and Roskanis , 2008 -RRB-	3474
interaction	3474
reactive astrocytes -LRB- Chuah et al. , 2011 ; Franssen et al. , 2007 ; Richter and Roskanis , 2008 -RRB-	3491
reactive astrocytes	3491
Chuah et al. , 2011 ; Franssen et al. , 2007 ; Richter and Roskanis , 2008	3512
Chuah	3512
et al. , 2011 ; Franssen et al. , 2007 ; Richter and Roskanis , 2008	3518
et al. , 2011	3518
et al.	3518
2011	3526
Franssen et al. , 2007	3532
Franssen	3532
et al. , 2007	3541
et al.	3541
2007	3549
Richter and Roskanis , 2008	3555
Richter and Roskanis	3555
2008	3577
modulation of inflammatory response -LRB- Chuah et al. , 2011 ; Lopez-Vales et al. , 2004b ; Torres-Espin et al. , 2013 -RRB-	3584
modulation	3584
inflammatory response -LRB- Chuah et al. , 2011 ; Lopez-Vales et al. , 2004b ; Torres-Espin et al. , 2013 -RRB-	3598
inflammatory response	3598
Chuah et al. , 2011 ; Lopez-Vales et al. , 2004b ; Torres-Espin et al. , 2013	3621
Chuah	3621
et al. , 2011 ; Lopez-Vales et al. , 2004b ; Torres-Espin et al. , 2013	3627
et al. , 2011	3627
et al.	3627
2011	3635
Lopez-Vales et al. , 2004b	3641
Lopez-Vales	3641
et al. , 2004b	3653
et al.	3653
2004b	3661
Torres-Espin et al. , 2013	3668
Torres-Espin	3668
et al. , 2013	3681
et al.	3681
2013	3689
promotion of neoangiogenesis -LRB- Lopez-Vales et al. , 2004a -RRB-	3696
promotion	3696
neoangiogenesis -LRB- Lopez-Vales et al. , 2004a -RRB-	3709
neoangiogenesis	3709
Lopez-Vales	3726
et al. , 2004a	3738
et al.	3738
2004a	3746
OECs	3763
their therapeutic effects	3774
their abilities to migrate and bridge damaged host tissue -LRB- Deng et al. , 2006 ; Pearse et al. , 2007 ; Ramon-Cueto et al. , 1998 ; Sasaki et al. , 2004 -RRB- , enhance axonal remylination -LRB- Dombrowski et al. , 2006 ; Imaizumi et al. , 1998 ; Sasaki et al. , 2004 -RRB- , induce neural regeneration -LRB- Li et al. , 1998 ; Lopez-Vales et al. , 2006 ; Ramer et al. , 2004 ; Witheford et al. , 2013 ; Ziegler et al. , 2011 -RRB- , modulate immune cells and phagocytose cellular debris and pathogens -LRB- He et al. , 2014 ; Leung et al. , 2008 -RRB-	3803
damaged host tissue -LRB- Deng et al. , 2006 ; Pearse et al. , 2007 ; Ramon-Cueto et al. , 1998 ; Sasaki et al. , 2004 -RRB- , enhance axonal remylination -LRB- Dombrowski et al. , 2006 ; Imaizumi et al. , 1998 ; Sasaki et al. , 2004 -RRB- , induce	3841
damaged host	3841
tissue -LRB- Deng et al. , 2006 ; Pearse et al. , 2007 ; Ramon-Cueto et al. , 1998 ; Sasaki et al. , 2004 -RRB- , enhance axonal remylination -LRB- Dombrowski et al. , 2006 ; Imaizumi et al. , 1998 ; Sasaki et al. , 2004 -RRB- ,	3854
tissue -LRB- Deng et al. , 2006 ; Pearse et al. , 2007 ; Ramon-Cueto et al. , 1998 ; Sasaki et al. , 2004 -RRB-	3854
tissue	3854
Deng et al. , 2006 ; Pearse et al. , 2007 ; Ramon-Cueto et al. , 1998 ; Sasaki et al. , 2004	3862
Deng	3862
et al. , 2006 ; Pearse et al. , 2007 ; Ramon-Cueto et al. , 1998 ; Sasaki et al. , 2004	3867
et al. , 2006	3867
et al.	3867
2006	3875
Pearse et al. , 2007	3881
Pearse	3881
et al. , 2007	3888
et al.	3888
2007	3896
Ramon-Cueto et al. , 1998	3902
Ramon-Cueto	3902
et al. , 1998	3914
et al.	3914
1998	3922
Sasaki et al. , 2004	3928
Sasaki	3928
et al. , 2004	3935
et al.	3935
2004	3943
axonal remylination -LRB- Dombrowski et al. , 2006 ; Imaizumi et al. , 1998 ; Sasaki et al. , 2004 -RRB-	3958
axonal remylination	3958
Dombrowski et al. , 2006 ; Imaizumi et al. , 1998 ; Sasaki et al. , 2004	3979
Dombrowski	3979
et al. , 2006 ; Imaizumi et al. , 1998 ; Sasaki et al. , 2004	3990
et al. , 2006	3990
et al.	3990
2006	3998
Imaizumi et al. , 1998	4004
Imaizumi	4004
et al. , 1998	4013
et al.	4013
1998	4021
Sasaki et al. , 2004	4027
Sasaki	4027
et al. , 2004	4034
et al.	4034
2004	4042
neural regeneration -LRB- Li et al. , 1998 ; Lopez-Vales et al. , 2006 ; Ramer et al. , 2004 ; Witheford et al. , 2013 ; Ziegler et al. , 2011 -RRB-	4056
neural regeneration	4056
Li et al. , 1998 ; Lopez-Vales et al. , 2006 ; Ramer et al. , 2004 ; Witheford et al. , 2013 ; Ziegler et al. , 2011	4077
Li	4077
et al. , 1998 ; Lopez-Vales et al. , 2006 ; Ramer et al. , 2004 ; Witheford et al. , 2013 ; Ziegler et al. , 2011	4080
et al. , 1998	4080
et al.	4080
1998	4088
Lopez-Vales et al. , 2006	4094
Lopez-Vales	4094
et al. , 2006	4106
et al.	4106
2006	4114
Ramer et al. , 2004	4120
Ramer	4120
et al. , 2004	4126
et al.	4126
2004	4134
Witheford et al. , 2013	4140
Witheford	4140
et al. , 2013	4150
et al.	4150
2013	4158
Ziegler et al. , 2011	4164
Ziegler	4164
et al. , 2011	4172
et al.	4172
2011	4180
immune cells and phagocytose cellular debris and pathogens -LRB- He et al. , 2014 ; Leung et al. , 2008 -RRB-	4196
immune cells and phagocytose cellular debris	4196
immune cells	4196
phagocytose cellular debris	4213
pathogens -LRB- He et al. , 2014 ; Leung et al. , 2008 -RRB-	4245
pathogens	4245
He	4256
et al. , 2014 ; Leung et al. , 2008	4259
et al.	4259
2014 ; Leung et al.	4267
2014	4267
Leung et al.	4273
Leung	4273
et al.	4279
2008	4287
the therapeutic effects of OECs	4303
the therapeutic effects	4303
OECs	4330
other studies	4362
behavioral improvements and spinal cord repair	4394
behavioral improvements	4394
spinal cord repair	4422
OECs transplantation	4447
Aoki et al. , 2010 ; Barakat et al. , 2005 ; Bretzner et al. , 2010 ; Lu et al. , 2006 ; Pearse et al. , 2007 ; Takami et al. , 2002	4469
Aoki	4469
et al. , 2010 ; Barakat et al. , 2005 ; Bretzner et al. , 2010 ; Lu et al. , 2006 ; Pearse et al. , 2007 ; Takami et al. , 2002	4474
et al. , 2010	4474
et al.	4474
2010	4482
Barakat et al. , 2005	4488
Barakat	4488
et al. , 2005	4496
et al.	4496
2005	4504
Bretzner et al. , 2010	4510
Bretzner	4510
et al. , 2010	4519
et al.	4519
2010	4527
Lu et al. , 2006	4533
Lu	4533
et al. , 2006	4536
et al.	4536
2006	4544
Pearse et al. , 2007	4550
Pearse	4550
et al. , 2007	4557
et al.	4557
2007	4565
Takami et al. , 2002	4571
Takami	4571
et al. , 2002	4578
et al.	4578
2002	4586
The conflicting outcomes	4593
several factors including the origions of OECs -LRB- Richter et al. , 2005 -RRB- , the culture conditions -LRB- Au et al. , 2007 -RRB- , the age -LRB- the number of passages -RRB- and purity of OECs -LRB- Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Novikova et al. , 2011 -RRB- , the delay between injury and OECs transplantation -LRB- Lopez-Vales et al. , 2004b , 2006 ; Torres-Espin et al. , 2013 -RRB- and the injury type and severity -LRB- Richter and Roskanis , 2008 -RRB-	4641
several factors	4641
the origions of OECs -LRB- Richter et al. , 2005 -RRB- , the culture conditions -LRB- Au et al. , 2007 -RRB- , the age -LRB- the number of passages -RRB- and purity of OECs -LRB- Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Novikova et al. , 2011 -RRB- , the delay between injury and OECs transplantation -LRB- Lopez-Vales et al. , 2004b , 2006 ; Torres-Espin et al. , 2013 -RRB- and the injury type and severity -LRB- Richter and Roskanis , 2008 -RRB-	4667
the origions	4667
OECs -LRB- Richter et al. , 2005 -RRB- , the culture conditions -LRB- Au et al. , 2007 -RRB- , the age -LRB- the number of passages -RRB- and purity of OECs -LRB- Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Novikova et al. , 2011 -RRB- , the delay between injury and OECs transplantation -LRB- Lopez-Vales et al. , 2004b , 2006 ; Torres-Espin et al. , 2013 -RRB- and the injury type and severity -LRB- Richter and Roskanis , 2008 -RRB-	4683
OECs -LRB- Richter et al. , 2005 -RRB- , the culture conditions -LRB- Au et al. , 2007 -RRB- , the age -LRB- the number of passages -RRB- and purity of OECs -LRB- Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Novikova et al. , 2011 -RRB-	4683
OECs -LRB- Richter et al. , 2005 -RRB-	4683
OECs	4683
Richter	4689
et al. , 2005	4697
et al.	4697
2005	4705
the culture conditions -LRB- Au et al. , 2007 -RRB-	4712
the culture conditions	4712
Au	4736
et al. , 2007	4739
et al.	4739
2007	4747
the age -LRB- the number of passages -RRB-	4754
the age	4754
the number of passages	4763
the number	4763
passages	4777
purity of OECs -LRB- Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Novikova et al. , 2011 -RRB-	4791
purity	4791
OECs -LRB- Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Novikova et al. , 2011 -RRB-	4801
OECs	4801
Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Novikova et al. , 2011	4807
Barnett and Riddell	4807
2007 ; Kawaja et al. , 2009 ; Novikova et al.	4828
2007	4828
Kawaja et al. , 2009 ; Novikova et al.	4834
Kawaja	4834
et al. , 2009 ; Novikova et al.	4841
et al. , 2009	4841
et al.	4841
2009	4849
Novikova et al.	4855
Novikova	4855
et al.	4864
2011	4872
the delay between injury and OECs transplantation -LRB- Lopez-Vales et al. , 2004b , 2006 ; Torres-Espin et al. , 2013 -RRB-	4879
the delay	4879
injury and OECs transplantation -LRB- Lopez-Vales et al. , 2004b , 2006 ; Torres-Espin et al. , 2013 -RRB-	4897
injury and OECs transplantation	4897
Lopez-Vales	4930
et al. , 2004b , 2006 ; Torres-Espin et al. , 2013	4942
et al.	4942
2004b , 2006 ; Torres-Espin et al.	4950
2004b , 2006	4950
2004b	4950
2006	4957
Torres-Espin et al.	4963
Torres-Espin	4963
et al.	4976
2013	4984
the injury type and severity -LRB- Richter and Roskanis , 2008 -RRB-	4994
the injury	4994
type and severity -LRB- Richter and Roskanis , 2008 -RRB-	5005
type and severity	5005
Richter and Roskanis , 2008	5024
Richter	5024
Roskanis , 2008	5036
Roskanis	5036
2008	5046
the hostile environment and adaptive immune response in the injured spinal cord	5073
the hostile environment	5073
adaptive immune response in the injured spinal cord	5101
adaptive immune response	5101
the injured spinal cord	5129
the survival rates of transplanted OECs are reported to be low , varying from approximately 0.3 % to 3 % -LRB- Barakat et al. , 2005 ; Pearse et al. , 2007 ; Roet et al. , 2012 ; Torres - Espin et al. , 2014 -RRB- , which indicates only a small number of transplanted OECs	5154
the survival rates of transplanted OECs are reported to be low	5154
the survival	5154
rates of transplanted OECs	5167
rates	5167
transplanted OECs	5176
varying from approximately 0.3 % to 3 % -LRB- Barakat et al. , 2005 ; Pearse et al. , 2007 ; Roet et al. , 2012 ; Torres - Espin et al. , 2014 -RRB-	5218
varying	5218
approximately 0.3 % to 3 % -LRB- Barakat et al. , 2005 ; Pearse et al. , 2007 ; Roet et al. , 2012 ; Torres - Espin et al. , 2014 -RRB-	5231
approximately 0.3 % to 3 %	5231
Barakat et al. , 2005 ; Pearse et al. , 2007 ; Roet et al. , 2012 ; Torres - Espin et al. , 2014	5257
Barakat	5257
et al. , 2005 ; Pearse et al. , 2007 ; Roet et al. , 2012 ; Torres - Espin et al. , 2014	5265
et al. , 2005	5265
et al.	5265
2005	5273
Pearse et al. , 2007	5279
Pearse	5279
et al. , 2007	5286
et al.	5286
2007	5294
Roet et al. , 2012	5300
Roet	5300
et al. , 2012	5305
et al.	5305
2012	5313
Torres - Espin et al. , 2014	5319
Torres	5319
Espin et al. , 2014	5327
Espin	5327
et al. , 2014	5333
et al.	5333
2014	5341
only a small number of transplanted OECs	5364
only a small number	5364
transplanted OECs	5387
beneficial effects	5411
a relatively short period post injury	5437
All these evidences	5476
the properties of OECs and the pathology of spinal cord injury	5512
the properties of OECs	5512
the properties	5512
OECs	5530
the pathology of spinal cord injury	5539
the pathology	5539
spinal cord injury	5556
us	5583
a novel OECs based therapy for SCI	5601
a novel OECs	5601
therapy for SCI	5620
therapy	5620
SCI	5632
Olfactory ensheathing cell conditioned medium	5637
Olfactory ensheathing cell	5637
OEC-M	5683
various neurotrophic factors that can promote neural regeneration	5699
various neurotrophic factors	5699
neural regeneration	5745
the repair of injured spinal cord -LRB- Lopez-Vales et al. , 2004b , 2006 ; Richter and Roskanis , 2008 ; Torres - Espin et al. , 2013 -RRB-	5777
the repair	5777
injured spinal cord -LRB- Lopez-Vales et al. , 2004b , 2006 ; Richter and Roskanis , 2008 ; Torres - Espin et al. , 2013 -RRB-	5791
injured spinal cord	5791
Lopez-Vales	5812
et al. , 2004b , 2006 ; Richter and Roskanis , 2008 ; Torres - Espin et al. , 2013	5824
et al.	5824
2004b , 2006 ; Richter and Roskanis , 2008 ; Torres - Espin et al.	5832
2004b , 2006	5832
2004b	5832
2006	5839
Richter and Roskanis , 2008	5845
Richter and Roskanis	5845
2008	5867
Torres - Espin et al.	5873
Torres	5873
Espin et al.	5881
Espin	5881
et al.	5887
2013	5895
the systemic delivery of OEC-M	5912
the systemic delivery	5912
OEC-M	5937
the low survival rate of grafted cells , the immune rejection , the surgery needed for the cell transplantation and other limitations of cell transplantation	5955
the low survival rate	5955
grafted cells	5980
the immune rejection	5995
the surgery needed for the cell transplantation	6017
the surgery	6017
the cell transplantation	6040
other limitations of cell transplantation	6069
other limitations	6069
cell transplantation	6090
the present study	6118
the consistent intraperitoneally administration of OEC-M	6172
the consistent intraperitoneally administration	6172
OEC-M	6223
functional recovery and axonal regeneration	6246
functional recovery	6246
axonal regeneration	6270
a contusive SCI	6296
The results	6313
a new cell-free OECs based therapy for spinal cord injury	6337
a new cell-free OECs	6337
therapy for spinal cord injury	6364
therapy	6364
spinal cord injury	6376
Results	6400
1	6414
OECs in culture with the nuclear staining -LRB- DAPI -RRB- and immunostained for P75NTR -LRB- × 200 -RRB- .	6417
OECs	6417
culture with the nuclear staining -LRB- DAPI -RRB- and immunostained for P75NTR -LRB- × 200 -RRB-	6425
culture with the nuclear staining -LRB- DAPI -RRB- and immunostained for P75NTR	6425
the nuclear staining -LRB- DAPI -RRB-	6438
the nuclear staining	6438
DAPI	6460
× 200	6496
The	6503
image	6513
> 90 % of cells were P75	6529
>	6529
90 % of cells	6531
90 %	6531
cells	6538
P75	6549
+	6552
Scale bar	6555
50 μm	6568
Fig. 2 .	6576
Fig.	6576
2	6581
Locomotion test	6584
The BBB open field locomotion score	6609
every three days	6659
the injury	6682
The number of rats -LRB- n -RRB- for each group at each time point	6694
The number	6694
rats -LRB- n -RRB- for each group at each time point	6708
rats -LRB- n -RRB-	6708
rats	6708
n	6714
each group at each time point	6721
each group	6721
each time point	6735
6	6754
Data	6757
mean ± SD	6781
The result	6792
significant differences	6813
the three groups	6843
surgery -LRB- two-way ANOVA , p < 0.05 -RRB-	6866
surgery	6866
two-way ANOVA , p < 0.05	6875
two-way ANOVA , p <	6875
two-way ANOVA	6875
p <	6890
p	6890
<	6892
0.05	6894
LSD-t-test	6901
two groups at each time point	6934
two groups	6934
each time point	6948
ap < 0.05 high dose OEC-M group vs. time-matched low dose OEC-M group ; bp < 0.05 high dose OEC-M group vs Con-M ; cp < 0.05 Con-M vs low dose OEC-M group .	6965
ap	6965
< 0.05 high dose	6968
<	6968
0.05 high dose	6970
OEC-M group vs. time-matched low dose OEC-M group ; bp < 0.05 high dose	6985
OEC-M group vs. time-matched low dose OEC-M group	6985
OEC-M group	6985
time-matched low dose OEC-M group	7001
bp < 0.05 high dose	7036
bp <	7036
bp	7036
0.05 high dose	7041
OEC-M group vs Con-M ; cp <	7056
OEC-M group vs Con-M	7056
OEC-M group	7056
Con-M	7071
cp <	7078
cp	7078
<	7081
0.05 Con-M vs low dose OEC-M group	7083
0.05 Con-M	7083
low dose OEC-M group	7097
Fig. 3 .	7120
Fig.	7120
3	7125
The concentration of BDNF in peripheral blood .	7128
The concentration	7128
BDNF	7149
peripheral blood	7157
ELISA	7175
the BDNF levels of test samples	7200
the BDNF levels	7200
test samples	7219
Con-M group -LRB- n = 6 -RRB- , low dose OEC-M group -LRB- n = 6 -RRB- and high dose OEC-M group -LRB- n = 6 -RRB-	7237
Con-M group -LRB- n = 6 -RRB-	7237
Con-M group	7237
n	7250
6	7252
low dose OEC-M group -LRB- n = 6 -RRB-	7256
low dose OEC-M group	7256
n	7278
6	7280
high dose OEC-M group -LRB- n = 6 -RRB-	7287
high dose OEC-M group	7287
n	7310
6	7312
week 1 , week 3 and week 6	7318
week 1	7318
week 3	7326
week 6	7337
Results	7358
mean ± SD	7383
-LRB- A -RRB- Comparisons	7394
two groups at a certain time point	7433
two groups	7433
a certain time point	7447
-LRB- B -RRB- BDNF levels	7469
-LRB- B -RRB-	7469
BDNF levels	7473
two time points in a certain group	7507
two time points	7507
a certain group	7526
ap < 0.05 high dose OEC-M group vs. low dose OEC-M group ; bp < 0.05 high dose OEC-M group vs Con-M ; cp < 0.05 Con-M vs low dose OEC-M group .	7543
ap	7543
< 0.05 high dose	7546
<	7546
0.05 high dose	7548
OEC-M group vs. low dose OEC-M group ; bp < 0.05 high dose	7563
OEC-M group vs. low dose OEC-M group	7563
OEC-M group	7563
low dose OEC-M group	7579
bp < 0.05 high dose	7601
bp <	7601
bp	7601
0.05 high dose	7606
OEC-M group vs Con-M ; cp <	7621
OEC-M group vs Con-M	7621
OEC-M group	7621
Con-M	7636
cp <	7643
cp	7643
<	7646
0.05 Con-M vs low dose OEC-M group	7648
0.05 Con-M	7648
low dose OEC-M group	7662
Fig. 4 .	7685
Fig.	7685
4	7690
The Fractional anisotropy -LRB- FA -RRB- value of the lesion segment .	7693
The Fractional anisotropy -LRB- FA -RRB-	7693
The Fractional anisotropy	7693
FA	7720
value of the lesion segment	7724
value	7724
the lesion segment	7733
Diffusion tensor imaging scan	7753
Diffusion tensor	7753
imaging	7770
the FA value of the rats -LRB- n = 6 -RRB-	7809
the FA value	7809
the rats -LRB- n = 6 -RRB-	7825
the rats	7825
n	7835
6	7837
each group every week	7845
each group	7845
every week	7856
the contusive spinal cord injury	7873
Results	7907
mean ± SD	7932
FA values	7943
SCI	7979
there	7987
differences among the three groups after surgery -LRB- two-way ANOVA , p < 0.05 -RRB-	8012
differences	8012
the three groups after surgery -LRB- two-way ANOVA , p < 0.05 -RRB-	8030
the three groups	8030
surgery -LRB- two-way ANOVA , p < 0.05 -RRB-	8053
surgery	8053
two-way ANOVA , p < 0.05	8062
two-way ANOVA , p <	8062
two-way ANOVA	8062
p <	8077
p	8077
<	8079
0.05	8081
LSD-t-test	8088
two groups at each time point	8121
two groups	8121
each time point	8135
ap < 0.05 high dose OEC-M group vs. low dose OEC-M group ; bp < 0.05 high dose OEC-M group vs Con-M ; cp < 0.05 Con-M vs low dose OEC-M group .	8152
ap	8152
< 0.05 high dose	8155
<	8155
0.05 high dose	8157
OEC-M group vs. low dose OEC-M group ; bp < 0.05 high dose	8172
OEC-M group vs. low dose OEC-M group	8172
OEC-M group	8172
low dose OEC-M group	8188
bp < 0.05 high dose	8210
bp <	8210
bp	8210
0.05 high dose	8215
OEC-M group vs Con-M ; cp <	8230
OEC-M group vs Con-M	8230
OEC-M group	8230
Con-M	8245
cp <	8252
cp	8252
<	8255
0.05 Con-M vs low dose OEC-M group	8257
0.05 Con-M	8257
low dose OEC-M group	8271
Fig. 5 .	8294
Fig.	8294
5	8299
T1-weighted images -LRB- T1WI -RRB- of the spinal cord after injury .	8302
T1-weighted images	8302
T1WI	8322
the spinal cord after injury	8331
the spinal cord	8331
injury	8353
T1WI	8361
less noticeable changes	8376
SCI	8406
The arrow	8411
the injury site	8431
Fig. 6 .	8449
Fig.	8449
6	8454
T2-weighted images -LRB- T2WI -RRB- of the spinal cord after injury .	8457
T2-weighted images	8457
T2WI	8477
the spinal cord after injury	8486
the spinal cord	8486
injury	8508
T2WI	8516
a hypointense region	8530
the spinal cord parenchyma , surrounded by a hperintense region at the contusive injury site	8558
the spinal cord parenchyma	8558
a hperintense region	8600
the contusive injury site	8624
The arrow	8651
the injury site	8671
Fig. 7 .	8689
Fig.	8689
7	8694
Diffusion tensor tractography -LRB- DTT -RRB- of SCI .	8697
Diffusion tensor tractography	8697
DTT	8728
SCI	8736
DTT	8741
the depression of the injured spinal cord and the interruption of the fiber tracks	8752
the depression of the injured spinal cord	8752
the depression	8752
the injured spinal cord	8770
the interruption of the fiber tracks	8798
the interruption	8798
the fiber tracks	8818
Fig. 8 .	8837
Fig.	8837
8	8842
Hematoxylin and eosin -LRB- HE -RRB- staining of lesion site .	8845
Hematoxylin and eosin -LRB- HE -RRB-	8845
Hematoxylin and eosin	8845
HE	8868
staining of lesion site	8872
staining	8872
lesion site	8884
All cell nucleuses	8897
Cytoplasm	8942
pink	8964
Scale bar	8970
200 μm	8983
Fig. 9 .	8992
Fig.	8992
9	8997
Immunohistochemistry staining of NF200 in the injury epicenter .	9000
Immunohistochemistry staining	9000
NF200	9033
the injury epicenter	9042
Positive axons and neuron	9064
Positive axons	9064
neuron	9083
brown	9103
All cell nucleuses	9110
Scale bar	9148
100 μm	9161
Fig. 10 .	9170
Fig.	9170
10	9175
Immunohistochemistry staining of NF200 in the region around the injury epicenter .	9179
Immunohistochemistry staining	9179
NF200	9212
the region around the injury epicenter	9221
the region	9221
the injury epicenter	9239
Positive axons and neuron	9261
Positive axons	9261
neuron	9280
brown	9300
All cell nucleuses	9307
Scale bar	9345
100 μm	9358
Fig. 11 .	9367
Fig.	9367
11	9372
The NF200 positive density in the gray matter .	9376
The NF200	9376
positive density in the gray matter	9386
positive density	9386
the gray matter	9406
NF200 positive density in the gray matter of the sections from Con-M group -LRB- n = 5 -RRB- , low dose OEC-M group -LRB- n = 5 -RRB- and high dose OEC-M group -LRB- n = 5 -RRB- at week 1 , week 3 and week 6	9423
NF200 positive density	9423
the gray matter of the sections from Con-M group -LRB- n = 5 -RRB- , low dose OEC-M group -LRB- n = 5 -RRB- and high dose OEC-M group -LRB- n = 5 -RRB- at week 1 , week 3 and week 6	9449
the gray matter	9449
the sections from Con-M group -LRB- n = 5 -RRB- , low dose OEC-M group -LRB- n = 5 -RRB- and high dose OEC-M group -LRB- n = 5 -RRB- at week 1 , week 3 and week 6	9468
the sections	9468
Con-M group -LRB- n = 5 -RRB- , low dose OEC-M group -LRB- n = 5 -RRB- and high dose OEC-M group -LRB- n = 5 -RRB-	9486
Con-M group -LRB- n = 5 -RRB-	9486
Con-M group	9486
n	9499
5	9501
low dose OEC-M group -LRB- n = 5 -RRB-	9505
low dose OEC-M group	9505
n	9527
5	9529
high dose OEC-M group -LRB- n = 5 -RRB-	9536
high dose OEC-M group	9536
n	9559
5	9561
week 1 , week 3 and week 6	9567
week 1	9567
week 3	9575
week 6	9586
Image	9612
Pro Plus 6	9618
Pro	9618
6	9627
Data	9630
mean ± SD	9652
-LRB- A -RRB- The NF200 positive density in the gray area	9663
-LRB- A -RRB-	9663
The NF200	9667
positive density in the gray area	9677
positive density	9677
the gray area	9697
two groups at week 1 , week 3 and week 6 post surgery	9732
two groups	9732
week 1 , week 3 and week 6 post surgery	9746
week 1	9746
week 3	9754
week 6 post surgery	9765
-LRB- B -RRB- LSD-t-test	9786
-LRB- B -RRB-	9786
LSD-t-test	9790
two time points in each group	9823
two time points	9823
each group	9842
ap < 0.05 high dose OEC-M group vs. low dose OEC-M group ; bp < 0.05 high dose OEC-M group vs Con-M ; cp < 0.05 Con-M vs low dose OEC-M group .	9854
ap	9854
< 0.05 high dose	9857
<	9857
0.05 high dose	9859
OEC-M group vs. low dose OEC-M group ; bp < 0.05 high dose	9874
OEC-M group vs. low dose OEC-M group	9874
OEC-M group	9874
low dose OEC-M group	9890
bp < 0.05 high dose	9912
bp <	9912
bp	9912
0.05 high dose	9917
OEC-M group vs Con-M ; cp <	9932
OEC-M group vs Con-M	9932
OEC-M group	9932
Con-M	9947
cp <	9954
cp	9954
<	9957
0.05 Con-M vs low dose OEC-M group	9959
0.05 Con-M	9959
low dose OEC-M group	9973
2.1	9996
Characterization of olfactory ensheathing cells	10001
Characterization	10001
olfactory ensheathing cells	10021
immunofluorescence	10052
200 × magnification	10077
different fields -LRB- n = 5 -RRB-	10097
different fields	10097
n	10115
5	10117
the fluorescence microscopy	10147
the purity of OECs	10188
the purity	10188
OECs	10202
the number of DAPI-labeled nuclei	10220
the number	10220
DAPI-labeled nuclei	10234
the number of P75NTR immunoreactive cells -LRB- rabbit anti-rat P75NTR monoclonal antibody , 1:50 Proteintech , Chicago , IL , USA -RRB-	10259
the number	10259
P75NTR immunoreactive cells -LRB- rabbit anti-rat P75NTR monoclonal antibody , 1:50 Proteintech , Chicago , IL , USA -RRB-	10273
P75NTR immunoreactive cells	10273
rabbit	10302
anti-rat P75NTR monoclonal antibody , 1:50 Proteintech , Chicago , IL , USA	10309
anti-rat P75NTR monoclonal antibody	10309
1:50 Proteintech , Chicago	10346
IL	10373
USA	10377
Our data	10383
93 ± 3.54 % of cells	10406
93 ± 3.54 %	10406
93	10406
cells	10420
P75NTR positive -LRB- Fig. 1 -RRB-	10431
P75NTR	10431
Fig. 1	10448
2.2	10457
Functional recovery evaluated by BBB	10462
Functional recovery	10462
BBB	10495
The BBB open field score	10505
the locomotor recovery	10551
SCI	10580
All the rats	10585
the surgery	10619
different degrees of recovery -LRB- Fig. 2 -RRB-	10645
different degrees	10645
recovery -LRB- Fig. 2 -RRB-	10666
recovery	10666
Fig. 2	10676
There	10685
significant differences among the Con-M group , the low dose OEC-M group and the high dose OEC-M group	10696
significant differences	10696
the Con-M group , the low dose OEC-M group and the high dose OEC-M group	10726
the Con-M group	10726
the low dose OEC-M group	10743
the high dose OEC-M group	10772
the 6 weeks	10805
the surgery -LRB- two-way ANOVA , p < 0.05 -RRB-	10823
the surgery	10823
two-way ANOVA , p < 0.05	10836
two-way ANOVA , p <	10836
two-way ANOVA	10836
p <	10851
p	10851
<	10853
0.05	10855
the early phase	10869
there	10886
no significant differences between groups	10897
no significant differences	10897
groups	10932
9 days to 42 days after surgery	10952
9 days	10952
42 days after surgery	10962
42 days	10962
surgery	10976
the Con-M group , BBB scores of the low dose	10998
the Con-M group	10998
BBB scores of the low dose	11015
BBB scores	11015
the low dose	11029
OEC-M group and high dose OEC-M group	11042
OEC-M group	11042
high dose OEC-M group	11058
significantly higher respectively -LRB- p < 0.05 -RRB-	11085
significantly higher respectively	11085
p < 0.05	11120
p	11120
< 0.05	11122
<	11122
0.05	11124
there	11135
a significant difference between high dose OEC-M group and low dose OEC-M at day 12 to day 30 after the surgery -LRB- p < 0.05 -RRB-	11150
a significant difference	11150
high dose OEC-M group and low dose OEC-M at day 12 to day 30 after the surgery -LRB- p < 0.05 -RRB-	11183
high dose OEC-M group and low dose OEC-M	11183
day 12 to day 30 after the surgery -LRB- p < 0.05 -RRB-	11227
day 12	11227
day 30 after the surgery -LRB- p < 0.05 -RRB-	11237
day 30	11237
the surgery -LRB- p < 0.05 -RRB-	11250
the surgery	11250
p < 0.05	11263
p	11263
< 0.05	11264
<	11264
0.05	11265
2.3	11272
Concentration of brain derived neurotrophic factor -LRB- BDNF -RRB- in peripheral blood determined by ELISA BDNF concentrations of the Con-M , OEC-M and peripheral blood	11277
Concentration	11277
brain derived neurotrophic factor -LRB- BDNF -RRB- in peripheral blood determined by ELISA BDNF concentrations of the Con-M , OEC-M and peripheral blood	11294
brain	11294
neurotrophic factor -LRB- BDNF -RRB-	11308
neurotrophic factor	11308
BDNF	11329
peripheral blood determined by ELISA BDNF concentrations of the Con-M , OEC-M and peripheral blood	11338
peripheral blood	11338
ELISA BDNF concentrations of the Con-M , OEC-M and peripheral blood	11369
ELISA BDNF concentrations	11369
the Con-M , OEC-M and peripheral blood	11398
the Con-M	11398
OEC-M	11409
peripheral blood	11419
ELISA -LRB- BNDF ELISA kit , CUSABIO , Wuhan , China -RRB-	11455
ELISA	11455
BNDF ELISA kit , CUSABIO , Wuhan , China	11462
BNDF ELISA kit	11462
CUSABIO	11478
Wuhan	11487
China	11494
The values of BDNF in the test samples	11502
The values	11502
BDNF in the test samples	11516
BDNF	11516
the test samples	11524
the standard curve	11566
It	11586
OEC-M and Con-M	11603
183.64 ± 12.61 pg/ml and 39.12 ± 14.21 pg/ml BDNF	11629
183.64 ± 12.61 pg/ml	11629
183.64	11629
12.61 pg/ml	11638
39.12 ± 14.21 pg/ml BDNF	11654
39.12	11654
14.21 pg/ml BDNF	11662
the systemic delivery of the treatment	11699
the systemic delivery	11699
the treatment	11724
BDNF in peripheral blood	11739
BDNF	11739
peripheral blood	11747
Fig. 3	11785
a major secretion of OEC	11797
a major secretion	11797
OEC	11818
the increased concentration of BDNF in the peripheral blood	11823
the increased concentration	11823
BDNF in the peripheral blood	11854
BDNF	11854
the peripheral blood	11862
the OEC secretome	11898
the blood	11951
the rat	11974
BDNF level	11983
significantly higher in the OEC-M treated groups -LRB- high dose and low dose OEC-M group -RRB-	11998
significantly higher in the OEC-M treated groups	11998
the OEC-M	12022
high dose and low dose OEC-M group	12048
high dose	12048
low dose OEC-M group	12062
the time-matched Con-M group at all three time points -LRB- p < 0.05 -RRB-	12096
the time-matched Con-M group	12096
all three time points -LRB- p < 0.05 -RRB-	12128
all three time points	12128
p < 0.05	12151
p	12151
< 0.05	12153
<	12153
0.05	12155
week 1	12165
BDNF level in high dose OEC-M group	12173
BDNF level	12173
high dose OEC-M group	12187
low dose group -LRB- p > 0.05 -RRB-	12234
low dose group	12234
p > 0.05	12250
p	12250
> 0.05	12252
>	12252
0.05	12254
significant differences	12270
these two groups	12310
week 3 and week 6	12330
week 3	12330
week 6	12341
injury -LRB- p < 0.05 -RRB- -LRB- Fig. 3A -RRB-	12354
injury -LRB- p < 0.05 -RRB-	12354
injury	12354
p < 0.05	12362
p	12362
< 0.05	12364
<	12364
0.05	12366
Fig. 3A	12373
There	12383
no significant differences in Con-M group between any time points -LRB- p > 0.05 -RRB-	12394
no significant differences	12394
Con-M group between any time points -LRB- p > 0.05 -RRB-	12424
Con-M group	12424
any time points -LRB- p > 0.05 -RRB-	12444
any time points	12444
p > 0.05	12461
p	12461
> 0.05	12463
>	12463
0.05	12465
the low dose OEC-M group and high dose OEC-M group	12486
the low dose OEC-M group	12486
high dose OEC-M group	12515
BDNF concentration in peripheral blood	12538
BDNF concentration	12538
peripheral blood	12560
week 1	12606
week 3	12616
the differences	12627
week 6 -LRB- p < 0.05 -RRB- -LRB- Fig. 3B -RRB-	12667
week 6 -LRB- p < 0.05 -RRB-	12667
week 6	12667
p < 0.05	12675
p	12675
< 0.05	12677
<	12677
0.05	12679
Fig. 3B	12686
2.4	12696
Quantitative analysis of the injured spinal crord by diffusion tensor imaging -LRB- DTI -RRB- Fraction anisotropy -LRB- FA -RRB-	12701
Quantitative analysis	12701
the injured spinal crord by diffusion tensor imaging -LRB- DTI -RRB- Fraction anisotropy -LRB- FA -RRB-	12726
the injured spinal crord by diffusion tensor imaging -LRB- DTI -RRB- Fraction anisotropy	12726
injured spinal crord by diffusion tensor imaging -LRB- DTI -RRB-	12730
injured spinal crord	12730
diffusion tensor imaging	12754
DTI	12780
FA	12806
a DTI quantitative parameter that reflects the axonal integrity and intensity -LRB- Deboy et al. , 2007 ; Kim et al. , 2007 ; Li et al. , 2015 ; Mukherjee , 2005 -RRB-	12813
a DTI quantitative parameter	12813
the axonal integrity and intensity -LRB- Deboy et al. , 2007 ; Kim et al. , 2007 ; Li et al. , 2015 ; Mukherjee , 2005 -RRB-	12856
the axonal integrity and intensity	12856
Deboy et al. , 2007 ; Kim et al. , 2007 ; Li et al. , 2015 ; Mukherjee , 2005	12892
Deboy	12892
et al. , 2007 ; Kim et al. , 2007 ; Li et al. , 2015 ; Mukherjee , 2005	12898
et al. , 2007	12898
et al.	12898
2007	12906
Kim et al. , 2007	12912
Kim	12912
et al. , 2007	12916
et al.	12916
2007	12924
Li et al. , 2015	12930
Li	12930
et al. , 2015	12933
et al.	12933
2015	12941
Mukherjee , 2005	12947
Mukherjee	12947
2005	12958
FA values	12965
the lesion segment of spinal cord -LRB- Fig. 4 -RRB-	12994
the lesion segment	12994
spinal cord -LRB- Fig. 4 -RRB-	13016
spinal cord	13016
Fig. 4	13029
FA values	13038
there	13072
significant differences among three groups	13083
significant differences	13083
three groups	13113
the surgery -LRB- two-way ANOVA , p < 0.05 -RRB-	13132
the surgery	13132
two-way ANOVA , p < 0.05	13145
two-way ANOVA , p <	13145
two-way ANOVA	13145
p <	13160
p	13160
<	13162
0.05	13164
FA values of the high dose OEC-M group	13171
FA values	13171
the high dose OEC-M group	13184
the Con-M group	13241
all time points	13260
surgery -LRB- p < 0.05 -RRB-	13282
surgery	13282
p < 0.05	13291
p	13291
< 0.05	13293
<	13293
0.05	13295
There	13302
no significant difference between the low dose OEC-M group and the Con - M group at week 1 post surgery	13312
no significant difference between the low dose OEC-M group and the Con	13312
no significant difference	13312
the low dose OEC-M group and the Con	13346
the low dose OEC-M group	13346
the Con	13375
M group at week 1 post surgery	13384
M group	13384
week 1 post surgery	13395
differences between these two groups	13425
differences	13425
these two groups	13445
week 2	13496
week 6 -LRB- p < 0.05 -RRB-	13506
week 6	13506
p < 0.05	13514
p	13514
< 0.05	13516
<	13516
0.05	13518
FA values of the high dose OEC-M group	13535
FA values	13535
the high dose OEC-M group	13548
the low dose OEC-M group	13605
week 3 , week 4 , week 5 , and week 6 post surgery	13633
week 3	13633
week 4	13641
week 5	13649
week 6 post surgery	13661
2.5	13682
Repair process of the injured spinal cord observed by MRI and diffusion tensor tractography -LRB- DTT -RRB- Conventional MRI , including the T1-weighted images -LRB- T1WI -RRB- and the T2-weighted images -LRB- T2WI -RRB-	13687
Repair process	13687
the injured spinal cord observed by MRI and diffusion tensor tractography -LRB- DTT -RRB- Conventional MRI , including the T1-weighted images -LRB- T1WI -RRB- and the T2-weighted images -LRB- T2WI -RRB-	13705
the injured spinal cord	13705
MRI and diffusion tensor tractography -LRB- DTT -RRB- Conventional MRI	13741
MRI	13741
diffusion tensor tractography -LRB- DTT -RRB- Conventional MRI	13749
diffusion tensor tractography	13749
DTT	13780
Conventional MRI	13785
the T1-weighted images -LRB- T1WI -RRB- and the T2-weighted images -LRB- T2WI -RRB-	13813
the T1-weighted images	13813
T1WI	13837
the T2-weighted images	13847
T2WI	13871
a 3.0 T MR scanner -LRB- Signa , GE Medical Systems , Milwaukee , Wisconsin , USA -RRB-	13894
a 3.0 T MR scanner	13894
Signa , GE Medical Systems , Milwaukee , Wisconsin , USA	13914
Signa	13914
GE Medical Systems	13921
Milwaukee	13941
Wisconsin	13952
USA	13963
T1WI	13969
present noticeable changes	13981
the SCI -LRB- Fig. 5 -RRB-	14014
the SCI	14014
Fig. 5	14023
T2WI	14041
clear differences	14055
groups	14079
the repair process of SCI -LRB- Fig. 6 -RRB-	14089
the repair process	14089
SCI -LRB- Fig. 6 -RRB-	14111
SCI	14111
Fig. 6	14116
the contusion site of the spinal cord	14142
the contusion site	14142
the spinal cord	14164
there	14181
a region with decreased signal intensity surrounded by a hyperintense region	14191
a region	14191
decreased signal intensity surrounded by a hyperintense region	14205
decreased signal intensity	14205
a hyperintense region	14246
the systemic delivery of the treatments	14275
the systemic delivery	14275
the treatments	14300
T2WI of the low dose OEC-M group and the high dose OEC-M group	14316
T2WI	14316
the low dose OEC-M group and the high dose OEC-M group	14324
the low dose OEC-M group	14324
the high dose OEC-M group	14353
a shrinkage of the circumambient hyperintense regions	14388
a shrinkage	14388
the circumambient hyperintense regions	14403
the shrinkage	14447
the high dose OEC-M group	14481
the low dose OEC-M group at all time points	14512
the low dose OEC-M group	14512
all time points	14540
contrast to the OEC-M treated groups	14560
contrast	14560
the OEC-M treated groups	14572
the hyperintense region of the Con-M group	14598
the hyperintense region	14598
the Con-M group	14625
both rostral and caudal directions	14653
both rostral	14653
caudal directions	14670
the injury site	14693
images of the Con-M group	14720
images	14720
the Con-M group	14730
an increased signal intensity of the hyperintense region over time	14759
an increased signal intensity	14759
the hyperintense region over time	14792
the hyperintense region	14792
time	14821
DTT	14827
the repair process of spinal cord tracts -LRB- Fig. 7 -RRB-	14862
the repair process	14862
spinal cord tracts -LRB- Fig. 7 -RRB-	14884
spinal cord tracts	14884
Fig. 7	14904
Results	14913
different characteristics of the nerve fiber	14931
different characteristics	14931
the nerve fiber	14960
different time points	14986
week 1 post surgery	15012
DTT of the spinal cord	15033
DTT	15033
the spinal cord	15040
the disruption of nerve tracks	15063
the disruption	15063
nerve tracks	15081
the edema of the spinal cord	15111
the edema	15111
the spinal cord	15124
depression of the white matter	15141
depression	15141
the white matter	15155
week 3	15192
injury	15205
there	15213
the irregularity of the nerve fiber	15233
the irregularity	15233
the nerve fiber	15253
clear depression at the injured site of spinal cord	15273
clear depression	15273
the injured site of spinal cord	15293
the injured site	15293
spinal cord	15313
The depression of the injury epicenter and the interruption of the fiber	15335
The depression of the injury epicenter	15335
The depression	15335
the injury epicenter	15353
the interruption of the fiber	15378
the interruption	15378
the fiber	15398
week 6	15427
surgery	15440
The tractography	15449
the OEC-M	15494
treated groups , the depression of the spinal cord at week 3 and week 6 , as well as the distortion of nerve tracks after the contusive injury ,	15504
treated groups	15504
the depression of the spinal cord at week 3 and week 6 , as well as the distortion of nerve tracks after the contusive injury	15520
the depression	15520
the spinal cord at week 3 and week 6 , as well as the distortion of nerve tracks after the contusive injury	15538
the spinal cord at week 3 and week 6	15538
the spinal cord	15538
week 3 and week 6	15557
week 3	15557
week 6	15568
the distortion of nerve tracks after the contusive injury	15587
the distortion	15587
nerve tracks after the contusive injury	15605
nerve tracks	15605
the contusive injury	15624
the Con-M group	15665
no obvious reconnection of nerve fiber at the injury epicenter	15691
no obvious reconnection	15691
nerve fiber at the injury epicenter	15718
nerve fiber	15718
the injury epicenter	15733
the DTT images	15767
the treatment	15788
2.6	15803
Morphology of the lesion site	15808
Morphology	15808
the lesion site	15822
hematoxylin and eosin -LRB- HE -RRB-	15850
hematoxylin and eosin	15850
HE	15873
staining At the magnification of 40 × , hematoxylin and eosin staining revealed the morphologic changes of the lesion site -LRB- Fig. 8 -RRB-	15877
staining	15877
the magnification of 40	15889
the magnification	15889
40	15910
× , hematoxylin and eosin staining	15912
the morphologic changes of the lesion site -LRB- Fig. 8 -RRB-	15955
the morphologic changes	15955
the lesion site -LRB- Fig. 8 -RRB-	15982
the lesion site	15982
Fig. 8	15999
the contusion	16014
disorganization of the lesion site , infiltration of the inflammatory cells , formation of the cavity and the scar formation at the injury site	16029
disorganization of the lesion site	16029
disorganization	16029
the lesion site	16048
infiltration of the inflammatory cells	16065
infiltration	16065
the inflammatory cells	16081
formation of the cavity	16105
formation	16105
the cavity	16118
the scar formation at the injury site	16133
the scar formation	16133
the injury site	16155
the HE	16189
all three groups	16208
week 1 post injury	16229
the differences of the morphologic changes at the lesion site	16249
the differences	16249
the morphologic changes at the lesion site	16268
the morphologic changes	16268
the lesion site	16295
three groups	16338
week 3	16364
the Con-M group	16384
the infiltration of cells	16401
the infiltration	16401
cells	16421
the injury site of OEC-M treated groups	16447
the injury site	16447
OEC-M treated groups	16466
week 6 post injury	16501
scar formation at the lesion site	16521
scar formation	16521
the lesion site	16539
the OEC-M treated groups , especially in the high dose OEC-M group	16575
the OEC-M treated groups , especially	16575
the OEC-M	16575
treated groups	16585
the high dose OEC-M group	16615
2.7	16642
Expression of NF200 determined by immunohistochemistry The expression of NF200 of the injured spinal cord segment	16647
Expression	16647
NF200 determined by immunohistochemistry The expression of NF200 of the injured spinal cord segment	16661
NF200	16661
immunohistochemistry	16681
The expression of NF200 of the injured spinal cord segment	16702
The expression	16702
NF200 of the injured spinal cord segment	16720
NF200	16720
the injured spinal cord segment	16729
immunohistochemistry	16779
A mouse anti-rat NF200	16801
- clonal antibody -LRB- 2 μg/ml , Abcam , Cambridge , MA , USA -RRB- and a rabbit anti-mouse biotin-labeled antibody -LRB- Biosynthesis , Beijing , China -RRB-	16828
- clonal antibody -LRB- 2 μg/ml , Abcam , Cambridge , MA , USA -RRB- and a rabbit anti-mouse biotin-labeled antibody	16828
clonal antibody -LRB- 2 μg/ml , Abcam , Cambridge , MA , USA -RRB-	16830
clonal antibody	16830
2 μg/ml , Abcam , Cambridge , MA , USA	16847
2 μg/ml	16847
Abcam	16856
Cambridge	16863
MA	16874
USA	16878
a rabbit anti-mouse biotin-labeled antibody	16887
a rabbit	16887
anti-mouse biotin-labeled antibody	16896
Biosynthesis	16932
Beijing	16946
China	16955
the primary and the secondary antibody	16978
the primary	16978
the secondary antibody	16994
sections	17034
there	17044
no axonal regeneration in the injury epicenter	17054
no axonal regeneration	17054
the injury epicenter	17080
the treatment -LRB- Fig. 9 -RRB-	17107
the treatment	17107
Fig. 9	17122
the results	17140
the Con-M	17179
OEC-M treatment	17190
the NF200 positive axonal regeneration	17218
the circumambient regions of the injury site -LRB- Fig. 10 -RRB-	17260
the circumambient regions	17260
the injury site -LRB- Fig. 10 -RRB-	17289
the injury site	17289
Fig. 10	17306
there	17320
more NF200 positive structures in the high dose OECM group than the low dose OEC-M group at all time points	17331
more NF200	17331
positive structures in the high dose OECM group than the low dose OEC-M group at all time points	17342
positive structures	17342
the high dose OECM group than the low dose OEC-M group at all time points	17365
the high dose OECM group	17365
the low dose OEC-M group at all time points	17395
the low dose OEC-M group	17395
all time points	17423
the injury	17445
The NF200 positive density in the gray matter	17457
The NF200 positive density	17457
the gray matter	17487
Fig. 11	17520
Statistical results	17530
all three groups	17566
the NF200 positive density in the gray matter	17584
the NF200 positive density	17584
the gray matter	17614
week 3 and week 6 post injury	17657
week 3	17657
week 6 post injury	17668
p < 0.05	17688
p	17688
< 0.05	17690
<	17690
0.05	17692
There	17699
significant differences between any two groups at all three time points -LRB- p < 0.05 -RRB-	17715
significant differences	17715
any two groups at all three time points -LRB- p < 0.05 -RRB-	17747
any two groups	17747
all three time points -LRB- p < 0.05 -RRB-	17765
all three time points	17765
p < 0.05	17788
p	17788
< 0.05	17790
<	17790
0.05	17792
Discussion Olfactory ensheathing cells	17803
OECs	17843
transplantation	17849
a promising candidate for the treatment of SCI	17874
a promising candidate	17874
the treatment of SCI	17900
the treatment	17900
SCI	17917
One of the highly recognized beneficial effects of OECs	17922
One	17922
the highly recognized beneficial effects of OECs	17929
the highly recognized beneficial effects	17929
OECs	17973
their expression of various neurotrophic factors and extracellular matrix components including BDNF , NGF , GDNF , Neurotrophin-4 / 5 -LRB- NT-4 / 5 -RRB- , neuregulin , secreted protein acidic rich in cysteine -LRB- SPARC -RRB- and matrix metalloproteinase 2 -LRB- MMP 2 -RRB- -LRB- Au et al. , 2007 ; Lipson et al. , 2003 ; Pastrana et al. , 2006 ; Richter and Roskanis , 2008 ; Woodhall et al. , 2001 -RRB-	17981
their expression of various neurotrophic factors	17981
their expression	17981
various neurotrophic factors	18001
extracellular matrix components including BDNF , NGF , GDNF , Neurotrophin-4 / 5 -LRB- NT-4 / 5 -RRB- , neuregulin , secreted protein acidic rich in cysteine -LRB- SPARC -RRB- and matrix metalloproteinase 2 -LRB- MMP 2 -RRB- -LRB- Au et al. , 2007 ; Lipson et al. , 2003 ; Pastrana et al. , 2006 ; Richter and Roskanis , 2008 ; Woodhall et al. , 2001 -RRB-	18034
extracellular matrix components	18034
BDNF , NGF , GDNF , Neurotrophin-4 / 5 -LRB- NT-4 / 5 -RRB- , neuregulin , secreted protein acidic rich in cysteine -LRB- SPARC -RRB- and matrix metalloproteinase 2 -LRB- MMP 2 -RRB- -LRB- Au et al. , 2007 ; Lipson et al. , 2003 ; Pastrana et al. , 2006 ; Richter and Roskanis , 2008 ; Woodhall et al. , 2001 -RRB-	18076
BDNF , NGF , GDNF , Neurotrophin-4 /	18076
BDNF	18076
Neurotrophin-4	18093
5 -LRB- NT-4 / 5 -RRB-	18108
5	18108
NT-4	18111
neuregulin , secreted protein acidic rich in cysteine -LRB- SPARC -RRB-	18120
neuregulin	18120
protein acidic rich	18141
protein	18141
cysteine -LRB- SPARC -RRB-	18164
cysteine	18164
SPARC	18174
matrix metalloproteinase 2 -LRB- MMP 2 -RRB- -LRB- Au et al. , 2007 ; Lipson et al. , 2003 ; Pastrana et al. , 2006 ; Richter and Roskanis , 2008 ; Woodhall et al. , 2001 -RRB-	18185
matrix metalloproteinase	18185
2 -LRB- MMP 2 -RRB- -LRB- Au et al. , 2007 ; Lipson et al. , 2003 ; Pastrana et al. , 2006 ; Richter and Roskanis , 2008 ; Woodhall et al. , 2001 -RRB-	18210
2 -LRB- MMP 2 -RRB-	18210
2	18210
MMP 2	18213
Au et al. , 2007 ; Lipson et al. , 2003 ; Pastrana et al. , 2006 ; Richter and Roskanis , 2008 ; Woodhall et al. , 2001	18221
Au	18221
et al. , 2007 ; Lipson et al. , 2003 ; Pastrana et al. , 2006 ; Richter and Roskanis , 2008 ; Woodhall et al. , 2001	18224
et al. , 2007	18224
et al.	18224
2007	18232
Lipson et al. , 2003	18238
Lipson	18238
et al. , 2003	18245
et al.	18245
2003	18253
Pastrana et al. , 2006	18259
Pastrana	18259
et al. , 2006	18268
et al.	18268
2006	18276
Richter and Roskanis , 2008	18282
Richter and Roskanis	18282
2008	18304
Woodhall et al. , 2001	18310
Woodhall	18310
et al. , 2001	18319
et al.	18319
2001	18327
the present study	18337
we	18356
a novel cell-free OECs based therapy to treat contusive spinal cord injury by the consistent intraperitoneally injection of OEC-M that contains the secretome of OECs	18376
a novel cell-free OECs	18376
therapy	18405
contusive spinal cord injury	18422
the consistent intraperitoneally injection of OEC-M	18454
the consistent intraperitoneally injection	18454
OEC-M	18500
the secretome of OECs	18520
the secretome	18520
OECs	18537
The results of this study	18543
The results	18543
this study	18558
the systemic delivery of OEC-M after SCI	18584
the systemic delivery	18584
OEC-M after SCI	18609
OEC-M	18609
SCI	18621
functional recovery	18634
axonal regeneration	18667
the injury epicenter	18694
the better therapeutic outcome	18726
the higher dose of OEC-M injection	18778
the higher dose	18778
OEC-M injection	18797
there	18829
no obvious axonal regeneration across the epicenter of injury in the rats treated with OEC-M	18839
no obvious axonal regeneration	18839
the epicenter of injury in the rats treated with OEC-M	18877
the epicenter	18877
injury in the rats treated with OEC-M	18894
injury	18894
the rats treated with OEC-M	18904
the rats	18904
OEC-M	18926
The therapeutic effects of OECs	18933
The therapeutic effects	18933
OECs	18960
the culture method , time in culture and purity of OECs	18995
the culture method	18995
time in culture and purity of OECs	19015
time	19015
culture and purity	19023
OECs	19045
It	19051
short-term cultured OECs purified with the method of differential cell adhesion	19074
short-term	19074
OECs purified with the method of differential cell adhesion	19094
OECs	19094
the method of differential cell adhesion	19113
the method	19113
differential cell adhesion	19127
better effects on the neural survival and axonal growth	19159
better effects	19159
the neural survival and axonal growth	19177
the neural survival	19177
axonal growth	19201
SCI -LRB- Novikova et al. , 2011 -RRB-	19221
SCI	19221
Novikova	19226
et al. , 2011	19235
et al.	19235
2011	19243
OECs age in culture	19259
OECs age	19259
culture	19271
their secretions	19280
example	19328
MMP 2 and SPARC that promote the neurite outgrowth and axonal regeneration	19337
MMP 2	19337
SPARC that promote the neurite outgrowth and axonal regeneration	19347
SPARC	19347
the neurite outgrowth and axonal regeneration	19366
the neurite outgrowth	19366
axonal regeneration	19392
late passage OECs -LRB- Au et al. , 2007 ; Pastrana et al. , 2006 -RRB-	19442
late passage OECs	19442
Au	19461
et al. , 2007 ; Pastrana et al. , 2006	19464
et al.	19464
2007 ; Pastrana et al.	19472
2007	19472
Pastrana et al.	19478
Pastrana	19478
et al.	19487
2006	19495
it	19512
4 -- 6 weeks in culture	19544
4	19544
6 weeks in culture	19546
6 weeks	19546
culture	19557
porcine OECs	19566
their phenotypic properties progressively -LRB- Radtke et al. , 2010 -RRB-	19605
their phenotypic properties progressively	19605
their phenotypic properties	19605
Radtke	19648
et al. , 2010	19655
et al.	19655
2010	19663
these , in the present study	19682
these	19682
the present study	19692
OECs	19711
postnatal day 2 rats	19736
postnatal day	19736
2 rats	19750
the differential cell adhesion method -LRB- Nash et al. , 2001 -RRB-	19770
the differential cell adhesion method	19770
Nash	19809
et al. , 2001	19814
et al.	19814
2001	19822
totally 2 weeks	19845
The purity of OECs	19862
The purity	19862
OECs	19876
more than 90 %	19902
the conditioned medium of OECs	19920
the conditioned medium	19920
OECs	19946
passage 1	19969
a previous research	19983
intraperitoneal injection of mice	20010
intraperitoneal injection	20010
mice	20039
embryonic stem cell conditioned medium	20044
embryonic stem cell	20044
ESC-M	20084
animals	20092
significant locomotor recovery	20109
SCI -LRB- Guo et al. , 2016 -RRB-	20146
SCI	20146
Guo	20151
et al. , 2016	20155
et al.	20155
2016	20163
accordance with that study	20173
accordance	20173
that study	20189
the functional benefit of OEC-M treatment in the present study	20201
the functional benefit	20201
OEC-M treatment in the present study	20227
OEC-M treatment	20227
the present study	20246
the BBB score	20281
It	20296
there	20319
no significant differences between high dose and low dose OEC-M groups	20330
no significant differences	20330
high dose and low dose OEC-M groups	20365
day 33	20404
day 42 post surgery	20414
contrast	20438
day 42 -LRB- week 6 -RRB- after the injury , compared to the low dose OEC-M group	20451
day 42 -LRB- week 6 -RRB-	20451
day 42	20451
week 6	20459
the injury	20473
the low dose OEC-M group	20497
the BDNF level in the high dose OEC-M group	20523
the BDNF level	20523
the high dose OEC-M group	20541
significant higher , as well as the NF200 positive density	20571
the NF200	20602
the gray matter	20632
This discrepancy	20649
the lordosis caused by the laminectomy of T9 and T10 segments without artificial stabilization that hindered the plantar stepping and hampered the BBB score	20684
the lordosis	20684
the laminectomy of T9 and T10 segments	20707
the laminectomy	20707
T9 and T10 segments	20726
artificial stabilization that hindered the plantar stepping	20754
artificial stabilization	20754
the plantar stepping	20793
the plantar	20793
the BBB score	20827
the NF200 immunohistochemistry staining	20852
the regeneration of axons	20907
the regeneration	20907
axons	20927
the area around the injury epicenter in all OEC-M treated groups	20951
the area	20951
the injury epicenter in all OEC-M treated groups	20967
the injury epicenter	20967
all OEC-M treated groups	20991
the functional recovery	21042
a certain extent	21069
the present study	21090
a major secretion of OECs	21112
a major secretion	21112
OECs	21133
the concentration of BDNF in peripheral blood	21139
the concentration	21139
BDNF in peripheral blood	21160
BDNF	21160
peripheral blood	21168
ELISA	21201
the secretome in the OEC-M	21218
the secretome	21218
the OEC-M	21235
the blood of animals	21279
the blood	21279
animals	21292
The ELISA results of our study	21301
The ELISA results	21301
our study	21322
the daily injection of OEC-M	21351
the daily injection	21351
OEC-M	21374
the BDNF concentrations	21381
the OEC-M treated groups , especially in the high dose group	21428
the OEC-M treated groups , especially	21428
the OEC-M	21428
treated groups	21438
the high dose group	21468
it	21498
BDNF	21528
the plasma and serum of different animals -LRB- Klein et al. , 2011 -RRB-	21552
the plasma and serum	21552
different animals -LRB- Klein et al. , 2011 -RRB-	21576
different animals	21576
Klein	21595
et al. , 2011	21601
et al.	21601
2011	21609
the Con-M that contained 10 % fetal bovine serum -LRB- FBS -RRB-	21637
the Con-M	21637
10 % fetal bovine serum -LRB- FBS -RRB-	21662
10 % fetal bovine serum	21662
FBS	21686
the BDNF levels in Con-M group	21692
the BDNF levels	21692
Con-M group	21711
Plasm BDNF levels in normal rats	21743
Plasm BDNF levels	21743
normal rats	21764
about 200 pg/ml -LRB- Cahir et al. , 2008 ; Mannari et al. , 2008 ; Radka et al. , 1996 -RRB-	21795
about 200 pg/ml	21795
Cahir et al. , 2008 ; Mannari et al. , 2008 ; Radka et al. , 1996	21812
Cahir	21812
et al. , 2008 ; Mannari et al. , 2008 ; Radka et al. , 1996	21818
et al. , 2008	21818
et al.	21818
2008	21826
Mannari et al. , 2008	21832
Mannari	21832
et al. , 2008	21840
et al.	21840
2008	21848
Radka et al. , 1996	21854
Radka	21854
et al. , 1996	21860
et al.	21860
1996	21868
the present study	21878
the daily injection of OEC-M which contains 183.64 ± 12.61 pg/ml BDNF	21897
the daily injection	21897
OEC-M which contains 183.64 ± 12.61 pg/ml BDNF	21920
OEC-M	21920
183.64	21941
12.61 pg/ml BDNF	21950
the plasma BDNF concentrations	21977
300 pg/ml at 6 weeks	22017
300 pg/ml	22017
6 weeks	22030
surgery	22044
previous study	22066
the blood-spinal cord barrier -LRB- BSCB -RRB-	22082
the blood-spinal cord barrier	22082
BSCB	22113
5 mins	22139
the mechanical trauma of spinal cord injury -LRB- Maikos and Shreiber , 2007 -RRB- and the disruption of BSCB	22152
the mechanical trauma	22152
spinal cord injury -LRB- Maikos and Shreiber , 2007 -RRB- and the disruption of BSCB	22177
spinal cord injury -LRB- Maikos and Shreiber , 2007 -RRB-	22177
spinal cord injury	22177
Maikos and Shreiber , 2007	22197
Maikos	22197
Shreiber , 2007	22208
Shreiber	22208
2007	22218
the disruption of BSCB	22228
the disruption	22228
BSCB	22246
28 days -LRB- Popovich et al. , 1996 -RRB-	22263
28 days	22263
Popovich	22272
et al. , 1996	22281
et al.	22281
1996	22289
the time course of the re-establishment of BSCB function	22307
the time course	22307
the re-establishment of BSCB function	22326
the re-establishment	22326
BSCB function	22350
varying results	22384
Noble and Wrathall , 1989 ; Popovich et al. , 1996	22414
Noble and Wrathall	22414
1989 ; Popovich et al.	22434
1989	22434
Popovich et al.	22440
Popovich	22440
et al.	22449
1996	22457
the MRI and immunohistochemistry	22486
the MRI	22486
immunohistochemistry	22498
the BSCB	22520
day 56	22557
traumatic SCI -LRB- Cohen et al. , 2009 -RRB-	22570
traumatic SCI	22570
Cohen	22585
et al. , 2009	22591
et al.	22591
2009	22599
these facts	22618
the absorbed BDNF in the blood , as well as other neurotrophic factors and extracellular matrix components	22631
the absorbed BDNF	22631
the blood , as well as other neurotrophic factors and extracellular matrix components	22652
the blood	22652
other neurotrophic factors and extracellular matrix components	22674
other neurotrophic factors	22674
extracellular matrix components	22705
the OEC-M	22742
the injured spinal cord	22773
the compromised BSCB	22805
their beneficial effects	22838
DTI	22864
a quantitative measurement based on the diffusion of water molecules in three dimensions	22871
a quantitative measurement	22871
the diffusion of water molecules in three dimensions	22907
the diffusion	22907
water molecules in three dimensions	22924
water molecules	22924
three dimensions	22943
Axonal membranes and myelin	22961
Axonal membranes	22961
myelin	22982
the water diffusion	23020
the axon tracts , which makes DTI applicable to study the pathophysiology of the nervous system -LRB- Basser , 1995 ; Beaulieu and Allen , 1994 -RRB-	23047
the axon tracts	23047
DTI	23076
the pathophysiology of the nervous system -LRB- Basser , 1995 ; Beaulieu and Allen , 1994 -RRB-	23100
the pathophysiology	23100
the nervous system -LRB- Basser , 1995 ; Beaulieu and Allen , 1994 -RRB-	23123
the nervous system	23123
Basser , 1995 ; Beaulieu and Allen , 1994	23143
Basser	23143
1995 ; Beaulieu and Allen	23151
1995	23151
Beaulieu and Allen	23157
1994	23177
the conventional MRI	23196
DTI parameters	23218
the pathophysiology processes	23280
the severity of injury following contusive SCI -LRB- Kelley et al. , 2014 ; Konomi et al. , 2012 ; Li et al. , 2015 ; Loy et al. , 2007 ; Patel et al. , 2016 -RRB-	23325
the severity	23325
injury following contusive SCI -LRB- Kelley et al. , 2014 ; Konomi et al. , 2012 ; Li et al. , 2015 ; Loy et al. , 2007 ; Patel et al. , 2016 -RRB-	23341
injury	23341
contusive SCI	23358
Kelley et al. , 2014 ; Konomi et al. , 2012 ; Li et al. , 2015 ; Loy et al. , 2007 ; Patel et al. , 2016	23373
Kelley	23373
et al. , 2014 ; Konomi et al. , 2012 ; Li et al. , 2015 ; Loy et al. , 2007 ; Patel et al. , 2016	23380
et al. , 2014	23380
et al.	23380
2014	23388
Konomi et al. , 2012	23394
Konomi	23394
et al. , 2012	23401
et al.	23401
2012	23409
Li et al. , 2015	23415
Li	23415
et al. , 2015	23418
et al.	23418
2015	23426
Loy et al. , 2007	23432
Loy	23432
et al. , 2007	23436
et al.	23436
2007	23444
Patel et al. , 2016	23450
Patel	23450
et al. , 2016	23456
et al.	23456
2016	23464
FA value , which reflects the anisotropy of the diffusion ,	23471
FA value	23471
the anisotropy of the diffusion	23496
the anisotropy	23496
the diffusion	23514
the most frequently used DTI parameter	23532
the SCI	23578
FA values of the injured regions	23587
FA values	23587
the injured regions	23600
Konomi et al. , 2012 ; Li et al. , 2015 ; Rajasekaran et al. , 2012	23649
Konomi	23649
et al. , 2012 ; Li et al. , 2015 ; Rajasekaran et al. , 2012	23656
et al. , 2012	23656
et al.	23656
2012	23664
Li et al. , 2015	23670
Li	23670
et al. , 2015	23673
et al.	23673
2015	23681
Rajasekaran et al. , 2012	23687
Rajasekaran	23687
et al. , 2012	23699
et al.	23699
2012	23707
the reduced FA values	23717
nerve degeneration and axonal loss -LRB- Deboy et al. , 2007 ; Mukherjee , 2005 -RRB-	23759
nerve degeneration	23759
axonal loss -LRB- Deboy et al. , 2007 ; Mukherjee , 2005 -RRB-	23782
axonal loss	23782
Deboy	23795
et al. , 2007 ; Mukherjee , 2005	23801
et al.	23801
2007 ; Mukherjee	23809
2007	23809
Mukherjee	23815
2005	23826
the present study	23836
our data	23855
the OEC-M treatment	23876
the FA values and the higher FA value	23916
the FA values	23916
the higher FA value	23934
higher dose of OEC-M injection	23975
higher dose	23975
OEC-M injection	23990
These results	24007
the administration of OEC-M	24031
the administration	24031
OEC-M	24053
SCI	24065
the nerve regeneration	24083
the axons	24119
the injury segment	24132
the FA value	24161
the whole transverse section of the injured spinal cord segment	24192
the whole transverse section	24192
the injured spinal cord segment	24224
the regeneration of axons in the area around the injury epicenter	24265
the regeneration	24265
axons in the area around the injury epicenter	24285
axons	24285
the area around the injury epicenter	24294
the area	24294
the injury epicenter	24310
the increase of FA values	24348
the increase	24348
FA values	24364
Conventional MRI	24375
the repair process of the injured spinal cord	24417
the repair process	24417
the injured spinal cord	24439
our study	24467
T1WI	24478
significant signal changes	24498
SCI	24531
T2WI , which is known to detect edema and hemorrhage ,	24547
T2WI	24547
edema and hemorrhage	24578
obvious differences	24609
different time points	24632
the SCI	24660
1 week after SCI	24672
1 week	24672
SCI	24685
the hypointense regions at the injury epicenter	24690
the hypointense regions	24690
the injury epicenter	24717
the hemorrhage	24748
the spinal cord	24770
the hyperintense region around the injury epicenter	24790
the hyperintense region	24790
the injury epicenter	24821
the segmental edema -LRB- Kawakyu-O ′ Connor et al. , 2016 ; Kumar and Hayashi , 2016 -RRB-	24860
the segmental edema	24860
Kawakyu-O ′ Connor et al. , 2016 ; Kumar and Hayashi , 2016	24881
Kawakyu-O ′ Connor	24881
et al. , 2016 ; Kumar and Hayashi , 2016	24898
et al. , 2016	24898
et al.	24898
2016	24906
Kumar and Hayashi , 2016	24912
Kumar and Hayashi	24912
2016	24931
the late time point -LRB- 3 week and 6 week -RRB- after injury	24950
the late time point -LRB- 3 week and 6 week -RRB-	24950
the late time point	24950
3 week and 6 week	24971
3 week	24971
6 week	24982
injury	24996
the hyperintense regions	25004
the hyperintense	25004
regions	25021
malacia	25050
Our results	25059
contrast	25087
the shrinkage of the hyperintense regions	25099
the shrinkage	25099
the hyperintense regions	25116
OEC-M treated group	25144
the hyperintense region of the Con-M group	25165
the hyperintense region	25165
the Con-M group	25192
both rostral and caudal directions	25220
both rostral	25220
caudal directions	25237
the injury site	25260
This extension	25277
the secondary injury process	25302
the initial trauma of spinal cord -LRB- Ambrozaitis et al. , 2006 ; Dumont et al. , 2001 ; Popovich et al. , 1997 -RRB-	25337
the initial trauma	25337
spinal cord -LRB- Ambrozaitis et al. , 2006 ; Dumont et al. , 2001 ; Popovich et al. , 1997 -RRB-	25359
spinal cord	25359
Ambrozaitis et al. , 2006 ; Dumont et al. , 2001 ; Popovich et al. , 1997	25372
Ambrozaitis	25372
et al. , 2006 ; Dumont et al. , 2001 ; Popovich et al. , 1997	25384
et al. , 2006	25384
et al.	25384
2006	25392
Dumont et al. , 2001	25398
Dumont	25398
et al. , 2001	25405
et al.	25405
2001	25413
Popovich et al. , 1997	25419
Popovich	25419
et al. , 1997	25428
et al.	25428
1997	25436
these	25455
the results of T2WI	25462
the results	25462
T2WI	25477
the OEC-M treatment	25495
the malacia	25523
the secondary injury following the initial trauma of the spinal cord	25550
the secondary injury	25550
the initial trauma of the spinal cord	25581
the initial trauma	25581
the spinal cord	25603
It	25620
DTT	25646
the injury epicenter	25663
the interrupted nerve fiber	25701
the intact tracts after various types of SCI -LRB- Li et al. , 2015 ; Wang et al. , 2014 -RRB-	25734
the intact tracts	25734
various types of SCI -LRB- Li et al. , 2015 ; Wang et al. , 2014 -RRB-	25758
various types	25758
SCI -LRB- Li et al. , 2015 ; Wang et al. , 2014 -RRB-	25775
SCI	25775
Li	25780
et al. , 2015 ; Wang et al. , 2014	25783
et al.	25783
2015 ; Wang et al.	25791
2015	25791
Wang et al.	25797
Wang	25797
et al.	25802
2014	25810
DTT	25828
the repair process of injured spinal cord	25865
the repair process	25865
injured spinal cord	25887
various kinds of interventions -LRB- Konomi et al. , 2012 -RRB-	25913
various kinds	25913
interventions -LRB- Konomi et al. , 2012 -RRB-	25930
interventions	25930
Konomi	25945
et al. , 2012	25952
et al.	25952
2012	25960
the present study	25970
DTT	25989
the overall shape of the contusive injury epicenter	26002
the overall shape	26002
the contusive injury epicenter	26023
the depression of the spinal cord and the distortion of the nerve tracks	26068
the depression of the spinal cord	26068
the depression	26068
the spinal cord	26086
the distortion of the nerve tracks	26106
the distortion	26106
the nerve tracks	26124
The tractography	26142
the OEC-M treatment	26169
the axonal regeneration	26210
the lesion epicenter , which was in accordance with our immunohistochemistry results	26241
the lesion epicenter	26241
accordance with our immunohistochemistry results	26276
accordance	26276
our immunohistochemistry results	26292
our results	26335
depression of the injured spinal cord and interruption of the nerve fibers	26365
depression	26365
the injured spinal cord and interruption of the nerve fibers	26379
the injured spinal cord	26379
interruption of the nerve fibers	26407
interruption	26407
the nerve fibers	26423
the OEC-M treatment	26459
previous studies	26493
the expression of various neurotrophic factors	26519
the expression	26519
various neurotrophic factors	26537
the transplanted OECs	26567
their beneficial effects	26595
the interaction with the astrocytes and neurons , as well as their bridging and migration across the lesion site -LRB- Chuah et al. , 2011 ; Chung et al. , 2004 ; Deng et al. , 2006 ; Pearse et al. , 2007 ; Sasaki et al. , 2004 -RRB-	26623
the interaction with the astrocytes and neurons	26623
the interaction	26623
the astrocytes and neurons	26644
their bridging and migration across the lesion site -LRB- Chuah et al. , 2011 ; Chung et al. , 2004 ; Deng et al. , 2006 ; Pearse et al. , 2007 ; Sasaki et al. , 2004 -RRB-	26683
their bridging	26683
their	26683
migration across the lesion site -LRB- Chuah et al. , 2011 ; Chung et al. , 2004 ; Deng et al. , 2006 ; Pearse et al. , 2007 ; Sasaki et al. , 2004 -RRB-	26702
migration	26702
the lesion site -LRB- Chuah et al. , 2011 ; Chung et al. , 2004 ; Deng et al. , 2006 ; Pearse et al. , 2007 ; Sasaki et al. , 2004 -RRB-	26719
the lesion site	26719
Chuah et al. , 2011 ; Chung et al. , 2004 ; Deng et al. , 2006 ; Pearse et al. , 2007 ; Sasaki et al. , 2004	26736
Chuah	26736
et al. , 2011 ; Chung et al. , 2004 ; Deng et al. , 2006 ; Pearse et al. , 2007 ; Sasaki et al. , 2004	26742
et al. , 2011	26742
et al.	26742
2011	26750
Chung et al. , 2004	26756
Chung	26756
et al. , 2004	26762
et al.	26762
2004	26770
Deng et al. , 2006	26776
Deng	26776
et al. , 2006	26781
et al.	26781
2006	26789
Pearse et al. , 2007	26795
Pearse	26795
et al. , 2007	26802
et al.	26802
2007	26810
Sasaki et al. , 2004	26816
Sasaki	26816
et al. , 2004	26823
et al.	26823
2004	26831
our hypothesis	26841
the low survival rate of grafted cells	26864
the low survival rate	26864
grafted cells	26889
only a small number of transplanted OECs	26904
only a small number	26904
transplanted OECs	26927
the bridging and migration effects during a relatively short period post injury	26970
the bridging and migration effects	26970
a relatively short period post injury	27012
there	27061
studies demonstrate the grafted OECs do not exhibit migratory property -LRB- Lu et al. , 2006 ; Pearse et al. , 2007 -RRB-	27076
studies	27076
the grafted OECs	27096
migratory property -LRB- Lu et al. , 2006 ; Pearse et al. , 2007 -RRB-	27128
migratory property	27128
Lu	27148
et al. , 2006 ; Pearse et al. , 2007	27151
et al.	27151
2006 ; Pearse et al.	27159
2006	27159
Pearse et al.	27165
Pearse	27165
et al.	27172
2007	27180
this	27199
we	27205
the cell-free OEC-M treatment , which enhanced the beneficial effects of neurotrophic factors and circumvented the limitation of cell survival , immune rejection and cell transplantation surgery ,	27216
the cell-free OEC-M treatment	27216
the beneficial effects of neurotrophic factors	27262
the beneficial effects	27262
neurotrophic factors	27288
the limitation of cell survival , immune rejection and cell transplantation surgery	27326
the limitation	27326
cell survival , immune rejection and cell transplantation surgery	27344
cell survival	27344
immune rejection	27359
cell transplantation surgery	27380
the recovery of SCI	27424
the recovery	27424
SCI	27440
the present study	27448
the HE staining	27467
HE	27471
the pathological changes	27492
the OEC-M treatment	27523
the OEC-M groups	27547
the infiltration of cells and the scar formation at the lesion site	27565
the infiltration	27565
cells and the scar formation at the lesion site	27585
cells	27585
the scar formation at the lesion site	27595
the scar formation	27595
the lesion site	27617
the Con-M group	27656
Our NF200 immunohistochemistry staining , which reacts broadly with axons and dendrites -LRB- Grady et al. , 1993 -RRB- ,	27673
Our NF200 immunohistochemistry staining	27673
axons and dendrites -LRB- Grady et al. , 1993 -RRB-	27740
axons and dendrites	27740
Grady	27761
et al. , 1993	27767
et al.	27767
1993	27775
the OEC-M treatment	27797
the axonal regeneration	27826
the lesion epicenter	27857
NF200 staining	27888
there	27915
no obvious axonal regeneration across the injury epicenter	27925
no obvious axonal regeneration	27925
the injury epicenter	27963
this	27988
the glial scar formed by the astrocytes that eventually blocks the axonal penetration	28011
the glial scar	28011
the astrocytes that eventually blocks the axonal penetration	28036
the astrocytes	28036
the axonal penetration	28074
conclusion	28101
the present study	28113
the systemic delivery of olfactory ensheathing cells conditioned medium	28144
the systemic delivery	28144
olfactory ensheathing cells conditioned medium	28169
olfactory ensheathing cells	28169
the recovery of contusive SCI	28225
the recovery	28225
contusive SCI	28241
the functional recovery	28268
axonal regeneration	28309
This novel cell-free OEC based therapy	28330
This novel cell-free OEC	28330
therapy	28361
the traditional limitations of OEC transplantation	28381
the traditional limitations	28381
OEC transplantation	28412
new possibilities for the future clinical applications	28444
new possibilities	28444
the future clinical applications	28466
SCI	28502
better axonal regeneration	28545
the specific factors	28585
these changes	28622
Materials and methods This study	28641
Materials	28641
methods This study	28655
methods	28655
This study	28663
the approval	28693
the Biomedical Ethics Committee of Medical College of Xi'an Jiaotong University	28709
the Biomedical Ethics Committee	28709
Medical College of Xi'an Jiaotong University	28744
Medical College	28744
Xi'an Jiaotong University	28763
The animal care and the experimental procedures	28790
The animal care	28790
the experimental procedures	28810
strict accordance	28856
the guidelines established by the National Institutes of Health	28879
the guidelines	28879
the National Institutes of Health	28909
the National Institutes	28909
Health	28936
4.1	28944
Culture and identification of OECs Following the procedures of Nash et al. , Olfactory bulbs	28949
Culture and identification	28949
OECs Following the procedures of Nash et al. , Olfactory bulbs	28979
OECs	28979
the procedures of Nash et al. , Olfactory bulbs	28994
the procedures	28994
Nash	29012
et al. , Olfactory bulbs	29017
et al.	29017
Olfactory bulbs	29025
2-D-old rats	29071
cold Hank 's balanced salt solution -LRB- HBSS , Invitrogen , Carlsbad , CA , USA -RRB-	29098
cold Hank 's balanced salt solution	29098
cold Hank 's	29098
HBSS	29134
Invitrogen , Carlsbad	29140
CA , USA	29162
The meninges and blood vessels	29172
fine forceps	29222
microscope and the olfactory nerve	29241
microscope	29241
the olfactory nerve	29256
glomerular layers	29280
small pieces	29318
0.25 % trypsin -LRB- Sigma -RRB-	29369
0.25 % trypsin	29369
Sigma	29384
5 min at 37 °C and 5 % CO2	29395
5 min at 37 °C	29395
5 min	29395
37 °C	29404
5 % CO2	29414
the termination of digestion by adding 10 % fetal bovine serum -LRB- FBS , Gibco -RRB-	29428
the termination	29428
digestion by adding 10 % fetal bovine serum -LRB- FBS , Gibco -RRB-	29447
digestion	29447
10 % fetal bovine serum -LRB- FBS , Gibco -RRB-	29467
10 % fetal bovine serum	29467
FBS	29491
Gibco	29496
the solution	29504
1000 rpm for 5 min	29536
1000 rpm	29536
5 min	29549
the supernatant	29559
The culture medium consisting of DF-12 medium -LRB- 1:1 mixture of DMEM and Ham 's F-12 -RRB- , 10 % fetal bovine serum and 1 % penicillin-streptomycin -LRB- Sigma -RRB-	29590
The culture medium	29590
DF-12 medium -LRB- 1:1 mixture of DMEM and Ham 's F-12 -RRB- , 10 % fetal bovine serum and 1 % penicillin-streptomycin -LRB- Sigma -RRB-	29623
DF-12 medium -LRB- 1:1 mixture of DMEM and Ham 's F-12 -RRB-	29623
DF-12 medium	29623
1:1 mixture of DMEM and Ham 's F-12	29637
1:1 mixture	29637
DMEM and Ham 's F-12	29652
DMEM	29652
Ham 's F-12	29661
Ham 's	29661
10 % fetal bovine serum	29674
1 % penicillin-streptomycin -LRB- Sigma -RRB-	29701
1 % penicillin-streptomycin	29701
Sigma	29729
the cell pellet	29759
The cells	29776
culture flasks -LRB- 25 cm2 , Nunclon , Thermo Scientific , Waltham , MA , USA -RRB-	29803
culture flasks	29803
25 cm2 , Nunclon , Thermo Scientific , Waltham , MA , USA	29819
25 cm2	29819
Nunclon	29827
Thermo Scientific	29836
Waltham	29855
MA	29864
USA	29868
differential attachment culture described by Nash et al. -LRB- 2001 -RRB- to purify the primary OECs	29877
differential attachment culture	29877
Nash	29922
et al. -LRB- 2001 -RRB-	29927
et al.	29927
2001	29935
the primary OECs	29951
purification and primary culture for 7 days	29975
purification and primary culture	29975
7 days	30012
cells	30020
slides coated with poly-L-lysine for immunofluorescence analysis	30059
slides	30059
poly-L-lysine for immunofluorescence analysis	30078
poly-L-lysine	30078
immunofluorescence analysis	30096
the attachment	30131
cells	30147
phosphate-buffered saline -LRB- PBS -RRB-	30168
phosphate-buffered saline	30168
PBS	30195
4 % PFA for 20 min	30222
4 % PFA	30222
20 min	30233
Non-specific protein binding	30241
a 60 min incubation	30285
10 % goat serum albumin -LRB- Sigma -RRB-	30310
10 % goat serum albumin	30310
Sigma	30334
room temperature	30344
Cells	30362
4 ℃ with a rabbit anti-rat P75NTR monoclonal antibody -LRB- 1:50 Proteintech , Chicago , IL , USA -RRB-	30396
4 ℃	30396
a rabbit anti-rat P75NTR monoclonal antibody -LRB- 1:50 Proteintech , Chicago , IL , USA -RRB-	30405
a rabbit anti-rat P75NTR monoclonal antibody	30405
a rabbit anti-rat P75NTR	30405
1:50 Proteintech , Chicago , IL , USA	30451
1:50 Proteintech , Chicago	30451
IL	30478
USA	30482
a 15 min wash in PBS	30500
a 15 min wash	30500
PBS	30517
Goat anti-rabbit antibody DyLight 488 -LRB- 1 ; 500 , Boster , China -RRB- was used as the secondary antibody and the cells	30522
Goat anti-rabbit antibody	30522
DyLight 488 -LRB- 1 ; 500 , Boster , China -RRB-	30548
DyLight 488	30548
1 ; 500 , Boster , China	30561
1 ; 500	30561
Boster , China	30568
the secondary antibody and the cells	30595
the secondary antibody	30595
the cells	30622
60 min at room temperature	30651
60 min	30651
room temperature	30661
a 15 min wash in PBS	30685
a 15 min wash	30685
PBS	30702
DAPI -LRB- 100 ng/ml -RRB-	30707
DAPI	30707
100 ng/ml	30713
10 min at room temperature	30738
10 min	30738
room temperature	30748
cells	30772
50 % glycerol	30794
Random areas	30808
the percentage of P75 positive cells	30843
the percentage	30843
P75 positive cells	30861
4.2	30894
Preparation of OEC conditioned medium	30899
Preparation	30899
OEC conditioned medium	30914
the purification and primary culture of OECs for 7 days	30943
the purification and primary culture	30943
OECs for 7 days	30983
OECs	30983
7 days	30992
cells	31000
the culture medium described above	31042
the culture medium	31042
The medium	31078
every two days	31101
the cell supernatant	31120
day 4 and day 6	31158
day 4	31158
day 6	31168
the subculturing	31180
These supernatants	31198
2500 rpm for 10 min	31237
2500 rpm	31237
10 min	31250
4 ℃	31260
a 0.4 μm filter	31290
debris	31316
The supernatant	31324
the OEC conditioned medium -LRB- OEC-M -RRB-	31358
the OEC conditioned medium	31358
OEC-M	31386
− 80 ℃	31407
The culture medium -LRB- without OECs -RRB-	31425
The culture medium	31425
OECs	31452
the control medium -LRB- Con-M -RRB-	31470
the control medium	31470
Con-M	31490
4.3	31498
Spinal cord surgery A total of 54 healthy adult male Sprague-Dawley rats weighing between 250 and 300 g	31503
Spinal cord surgery A total	31503
54 healthy adult male Sprague-Dawley rats weighing between 250 and 300 g	31534
54 healthy adult male Sprague-Dawley rats	31534
between 250 and 300 g	31585
preoperative environmental adaption for 2 weeks with free access	31620
preoperative environmental adaption	31620
2 weeks with free access	31660
2 weeks	31660
free access	31673
food and water	31688
room temperature	31706
Rats	31724
intraperitoneal injection of sodium pentobarbital	31752
intraperitoneal injection	31752
sodium pentobarbital	31781
40 mg/kg body weight	31805
The laminectomy	31827
T9-10	31865
the spinal cord	31881
The spinal cord injury	31898
T10 segment	31935
the NYU weight-drop impactor -LRB- New York University , New York , USA -RRB- with a 10 g rod	31953
the NYU weight-drop impactor -LRB- New York University , New York , USA -RRB-	31953
the NYU weight-drop impactor	31953
New York University	31983
New York	32004
USA	32014
a 10 g rod	32024
a height of 25.0 mm	32048
a height	32048
25.0 mm	32060
Hemorrhage and edema in the injured area , as well as the tail wagging and hind limb fluttering	32069
Hemorrhage and edema	32069
the injured area , as well as the tail wagging and hind limb fluttering	32093
the injured area	32093
the tail wagging and hind limb fluttering	32122
the tail wagging	32122
hind limb fluttering	32143
the successful modeling of contusive spinal cord injury	32175
the successful modeling	32175
contusive spinal cord injury	32202
the muscles and skins	32244
separate layers	32282
Gentamicin -LRB- 5 mg/kg -RRB-	32299
Gentamicin	32299
5 mg/kg	32311
the surgery	32361
7 days	32392
Buprenorphine -LRB- 0.01 mg/kg -RRB-	32403
Buprenorphine	32403
0.01 mg/kg	32418
subcutaneous injection for 3 days	32473
subcutaneous injection	32473
3 days	32500
Rats	32508
free access	32534
food and water	32549
manual bladder evacuation	32577
twice every day	32603
normal function	32625
4.4	32651
Treatment groups and BBB scores	32656
Treatment groups	32656
BBB scores	32677
the study of treatment effects	32692
the study	32692
treatment effects	32705
the animals	32724
Con-M group -LRB- n = 18 -RRB- , low-dose OEC-M group -LRB- n = 18 -RRB- , and high-dose OEC-M group -LRB- n = 18 -RRB-	32754
Con-M group -LRB- n = 18 -RRB-	32754
Con-M group	32754
n	32767
18	32769
low-dose OEC-M group -LRB- n = 18 -RRB-	32774
low-dose OEC-M group	32774
n	32796
18	32798
high-dose OEC-M group -LRB- n = 18 -RRB-	32807
high-dose OEC-M group	32807
n	32830
18	32832
Different reagents	32837
rat	32899
surgery	32915
the rats	32929
The rats in the Con-M group	32955
The rats	32955
the Con-M group	32967
2 ml Con-M	33002
2 ml mixed medium -LRB- 1 ml OEC-M and 1 ml Con-M -RRB- and 2 ml OEC-M	33025
2 ml mixed medium -LRB- 1 ml OEC-M and 1 ml Con-M -RRB-	33025
2 ml mixed medium	33025
2 ml	33025
1 ml OEC-M and 1 ml Con-M	33044
1 ml OEC-M	33044
1 ml Con-M	33059
2 ml OEC-M	33075
the rats in the low-dose OEC-M group and high-dose OEC-M group	33102
the rats	33102
the low-dose OEC-M group and high-dose OEC-M group	33114
the low-dose OEC-M group	33114
high-dose OEC-M group	33143
The Basso , Beattie and Bresnahan	33179
BBB	33213
scores -LRB- Basso et al. , 1995 -RRB-	33218
scores	33218
Basso	33226
et al. , 1995	33232
et al.	33232
1995	33240
two independent and blinded observers	33264
every three days	33302
the surgery until sacrificed	33325
the surgery	33325
4.5	33355
MRI , DTI and DTT scan Eighteen rats -LRB- Six rats per group -RRB- were randomly chosen to do the diffusion tensor imaging -LRB- DTI -RRB-	33360
MRI , DTI	33360
DTT scan Eighteen rats -LRB- Six rats per group -RRB- were randomly chosen to do the diffusion tensor imaging -LRB- DTI -RRB-	33373
DTT	33373
Eighteen rats -LRB- Six rats per group -RRB-	33382
Eighteen rats	33382
Six rats per group	33397
Six rats	33397
group	33410
the diffusion tensor imaging	33444
DTI	33474
every week	33484
the surgery	33501
Conventional MRI	33514
day 7 , 21 and 42 post surgery	33549
day 7	33549
21	33556
42 post surgery	33563
The animals	33580
sodium pentobarbital	33615
40 mg/kg	33637
a supine position within a specialized coil designed for scanning rats	33666
a supine position	33666
a specialized coil designed for scanning rats	33691
a specialized coil	33691
scanning rats	33723
All the scans	33738
a 3.0 T MR scanner -LRB- Signa , GE Medical Systems , Milwaukee , Wisconsin , USA -RRB-	33778
a 3.0 T MR scanner	33778
Signa , GE Medical Systems , Milwaukee , Wisconsin , USA	33798
Signa	33798
GE Medical Systems	33805
Milwaukee	33825
Wisconsin	33836
USA	33847
SE sequence	33853
the conventional MRI	33886
T1-weighted and T2-weighted images	33928
single shot spinecho planar imaging -LRB- EPI -RRB- sequence	33968
single shot spinecho planar imaging -LRB- EPI -RRB-	33968
sequence	34010
the DTI images	34042
The relevant parameters for conventional MRI and DTI of this study	34058
The relevant parameters	34058
conventional MRI and DTI	34086
this study	34114
strict accordance with Li	34133
strict accordance	34133
Li	34156
et al. -LRB- 2015 -RRB-	34159
et al.	34159
2015	34167
the	34180
the data	34190
a separate workstation -LRB- Advantage windows workstation , version 4.2 , GE Healthcare , Waukesha , Wisconsin , USA -RRB-	34219
a separate workstation	34219
Advantage windows workstation , version 4.2 , GE Healthcare , Waukesha , Wisconsin , USA	34243
Advantage windows workstation	34243
version 4.2	34274
GE Healthcare	34287
Waukesha	34302
Wisconsin	34312
USA	34323
the quantitative DTI parameter -LRB- FA value -RRB-	34341
the quantitative DTI parameter	34341
FA value	34373
Diffusion tensor tractography -LRB- DTT -RRB- of the injury site	34384
Diffusion tensor tractography -LRB- DTT -RRB-	34384
Diffusion tensor tractography	34384
DTT	34415
the injury site	34423
the FuncTool software -LRB- GE Healthcare -RRB-	34463
the FuncTool software	34463
GE Healthcare	34486
4.6	34502
Perfusion and tissue processing Rats	34507
7 , 21 and 42 days after the MRI and DTI scan -LRB- n = 18 for each time point , 6 rats per group -RRB-	34583
7	34583
21 and 42 days after the MRI and DTI scan -LRB- n = 18 for each time point , 6 rats per group -RRB-	34586
21 and 42 days	34586
the MRI and DTI	34607
n = 18 for each time point , 6 rats per group	34629
n = 18	34629
n	34629
18	34632
each time point , 6 rats per group	34639
each time point	34639
6 rats per group	34656
6 rats	34656
group	34667
the deep anesthesia by sodium pentobarbital -LRB- 40 mg/kg , i.p. -RRB-	34681
the deep anesthesia	34681
sodium pentobarbital -LRB- 40 mg/kg , i.p. -RRB-	34704
sodium pentobarbital	34704
40 mg/kg , i.p.	34726
40 mg/kg	34726
plasma	34743
the heart with EDTA	34769
the heart	34769
EDTA	34784
the anticoagulant when the rats were still in deep anesthesia	34792
the anticoagulant	34792
the rats	34815
deep anesthesia	34838
Rats	34855
0.9 % saline followed by 4 % paraformaldehyde	34899
0.9 % saline	34899
4 % paraformaldehyde	34923
The spinal cord segment from 1 cm caudal to 1 cm rostral of the injury epicenter	34944
The spinal cord segment	34944
1 cm caudal to 1 cm rostral of the injury epicenter	34973
1 cm caudal	34973
1 cm rostral of the injury epicenter	34988
1 cm rostral	34988
the injury epicenter	35004
the vertebral column and post-fixed in 4 % paraformaldehyde overnight	35044
the vertebral column	35044
post-fixed in 4 % paraformaldehyde overnight	35069
4 % paraformaldehyde	35083
4 ℃	35116
The tissues	35121
an ascending series of ethanol solutions	35157
an ascending series	35157
ethanol solutions	35180
xylene	35212
paraffin	35241
the paraffin blocks	35257
horizontal serial sections of 7 μm thickness	35291
horizontal serial sections	35291
7 μm thickness	35321
4.7	35337
ELISA The plasma samples	35342
ELISA	35342
The plasma samples	35348
3000g	35387
20 min at 4 ℃	35397
20 min	35397
4 ℃	35407
− 20 ℃	35430
ELISA	35437
the protocol of rat BNDF ELISA kit -LRB- CUSABIO , Wuhan , China -RRB- to measure the BDNF concentrations of OEC-M , Con-M and rats plasma samples	35467
the protocol	35467
rat BNDF ELISA kit -LRB- CUSABIO , Wuhan , China -RRB-	35483
rat BNDF ELISA kit	35483
CUSABIO	35503
Wuhan	35512
China	35519
the BDNF concentrations of OEC-M , Con-M and rats plasma samples	35537
the BDNF concentrations	35537
OEC-M , Con-M and rats plasma samples	35564
Values of BDNF	35602
Values	35602
BDNF	35612
the standard curve	35642
4.8	35662
Hematoxylin-eosin staining Sections	35667
dimethylbenzene	35719
decreasing concentrations of ethanol	35755
decreasing concentrations	35755
ethanol	35784
PBS	35807
hematoxylin	35830
5 min	35846
The tissue sections	35853
water followed by 1 % HCl in ethanol solution for 30 s	35888
water	35888
1 % HCl in ethanol solution for 30 s	35906
1 % HCl	35906
ethanol solution for 30 s	35916
ethanol solution	35916
30 s	35937
eosin for 6 min	35963
eosin	35963
6 min	35973
sections	35980
increasing concentrations of ethanol and dimethylbenzene	36013
increasing concentrations	36013
ethanol and dimethylbenzene	36042
4.9	36071
Immunohistochemistry Immunohistochemistry	36076
the expression of NF200	36142
the expression	36142
NF200	36160
Sections	36167
dimethylbenzene for 1 h	36191
dimethylbenzene	36191
1 h	36211
a descending ethanol solution series	36242
the rehydration by distilled water	36286
the rehydration	36286
distilled water	36305
endogenous peroxidase activity	36322
the incubation of 3 % hydrogen peroxide for 20 min	36368
the incubation	36368
3 % hydrogen peroxide for 20 min	36386
3 % hydrogen peroxide	36386
20 min	36411
Heatinduced epitope retrieval method	36419
the antigenic sites	36475
sections	36505
10 mmol/L sodium citrate buffer -LRB- pH 6.0 -RRB-	36529
10 mmol/L sodium citrate buffer	36529
pH 6.0	36562
a microwave oven	36577
98 ℃ for 20 min	36597
98 ℃	36597
20 min	36606
cold water for 10 min	36626
cold water	36626
10 min	36641
PBS	36668
Sections	36673
10 % goat serum albumin -LRB- Sigma -RRB-	36705
10 % goat serum albumin	36705
Sigma	36729
60 min at room temperature	36740
60 min	36740
room temperature	36750
the non-specific protein binding	36776
the 12 h incubation at 4 °C with a mouse anti-rat NF200 monoclonal antibody -LRB- 2 μg/ml , Abcam , Cambridge , MA , USA -RRB-	36822
the 12 h incubation	36822
4 °C with a mouse anti-rat NF200 monoclonal antibody -LRB- 2 μg/ml , Abcam , Cambridge , MA , USA -RRB-	36845
4 °C	36845
a mouse anti-rat NF200 monoclonal antibody -LRB- 2 μg/ml , Abcam , Cambridge , MA , USA -RRB-	36855
a mouse anti-rat NF200 monoclonal antibody	36855
a mouse anti-rat NF200	36855
2 μg/ml , Abcam , Cambridge , MA , USA	36899
2 μg/ml	36899
Abcam	36908
Cambridge	36915
MA	36926
USA	36930
a 15 min rinse in PBS	36942
a 15 min rinse	36942
PBS	36960
a rabbit anti-mouse biotin-labeled secondary antibody -LRB- Beijing Biosynthesis -RRB-	36965
a rabbit anti-mouse biotin-labeled secondary antibody	36965
a rabbit	36965
anti-mouse biotin-labeled secondary antibody	36974
Beijing Biosynthesis	37020
sections	37061
HRP-conjugated streptavidin -LRB- Beijing Biosynthesis -RRB- for 30 min	37090
HRP-conjugated streptavidin -LRB- Beijing Biosynthesis -RRB-	37090
HRP-conjugated streptavidin	37090
Beijing Biosynthesis	37119
30 min	37145
25 ℃	37155
Diaminobenzidine -LRB- DAB -RRB- and hematoxylin	37161
Diaminobenzidine -LRB- DAB -RRB-	37161
Diaminobenzidine	37161
DAB	37179
hematoxylin	37188
reagent and counterstain	37213
The micrographs	37239
Image	37272
Pro Plus 6 -LRB- Media Cybernetics , USA -RRB-	37278
Pro	37278
6	37287
Media Cybernetics	37290
USA	37309
NF200-labeled area in the gray matter in each section	37315
NF200-labeled area	37315
the gray matter in each section	37337
the gray matter	37337
each section	37356
a threshold for background correction	37397
a threshold	37397
background correction	37413
NF200 positive density in the gray matter	37444
NF200 positive density	37444
the gray matter	37470
4.10	37502
Statistical analysis SPSS 23.0 -LRB- SPSS Inc , Chicago , IL , USA -RRB-	37508
Statistical analysis SPSS 23.0	37508
Statistical analysis	37508
SPSS 23.0	37529
SPSS Inc , Chicago , IL , USA	37540
SPSS Inc	37540
Chicago	37550
IL	37559
USA	37563
the statistical analyses	37581
Results	37607
the figures	37625
mean ± SD with n	37655
mean ± SD	37655
n	37670
the number of replicates	37685
the number	37685
LSD test	37711
the statistical significance between two groups	37741
the statistical significance	37741
two groups	37778
comparisons among multiple groups	37793
comparisons	37793
multiple groups	37811
two-way ANOVA of repeated measures	37848
two-way ANOVA	37848
repeated measures	37865
P	37884
0.05	37888
all the comparisons	37923
